<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2006222222
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2017
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        DIOSTAR PLUS
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        VALSARTAN,HYDROCHLOROTHIAZIDE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        160,12.5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        24.5
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Pharma International Co." />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Pharma International Co.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 513]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SAUDI ARABIAN DRUG STORE COMPANY
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Pharma International Co.
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        C09DA03
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="margin-right:0cm; text-align:left"><strong>Diostar-plus</strong><strong>&reg; </strong>Film coated tablets contain two active substances called valsartan and hydrochlorothiazide. Both of these substances help to control high blood pressure )hypertension(.</p><p style="margin-left:40px; text-align:left; text-indent:-5.5pt">. <strong>Valsartan </strong>belongs to a group of medicines known as angiotensin II receptor antagonists, which help control high blood pressure. Angiotensin II is a substance in the body that causes vessels to tighten, thus causing your blood pressure to increase. Valsartan works by blocking the effect of angiotensin</p><p style="margin-left:40px; text-align:left">II. As a result, blood vessels relax and blood pressure is lowered.</p><p style="margin-left:40px; margin-right:5.15pt; text-align:left; text-indent:-4.45pt">. <strong>Hydrochlorothiazide </strong>belongs to a group of medicines called thiazide diuretics )also known as &rdquo;water tablets&ldquo;(. Hydrochlorothiazide increases urine output, which also lowers blood pressure.</p><p style="text-align:left">&nbsp;</p><p style="text-align:left">Diostar-plus&reg; tablets are used to treat high blood pressure which is not adequately controlled by a single substance alone.</p><p style="text-align:left"><strong>&nbsp;</strong></p><p style="text-align:left">High blood pressure increases the workload of the heart and arteries. If not treated, it can damage the blood vessels of the brain, heart, and kidneys, and may result in a stroke, heart failure or kidney failure. High blood pressure increases the risk of heart attacks. Lowering your blood pressure to normal reduces the risk of developing these disorders.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="text-align:left">&nbsp;<!--[endif]-->Do not take Diostar-plus&reg; tablets:</p><p style="margin-left:120.6pt; margin-right:2.35pt; text-align:left; text-indent:-4.05pt">. If you are allergic )hypersensitive( to valsartan, hydrochlorothiazide, sulphonamide derivatives )substanc es chemically related to hydrochlorothiazide( or to any of the other ingredients of <strong>Diostar-plus</strong><strong>&reg;</strong><strong>&nbsp;tablets</strong>.</p><p style="margin-left:121pt; margin-right:0cm; text-align:left; text-indent:-4.45pt">. If you are <strong>more than 3 months pregnant </strong>)it is also better to avoid Valsartan / Hydrochlorothiazide tablets in early pregnancy - see pregnancy section(.</p><p style="margin-left:121pt; text-align:left; text-indent:-4.45pt">. If you have <strong>severe </strong>liver disease, destruction of the small bile ducts within the liver )biliary cirrhosis( leading to the build up of bile in the liver )cholestasis(.</p><p style="margin-left:116.55pt; text-align:left">. If you have <strong>severe </strong>kidney disease.</p><p style="margin-left:116.55pt; text-align:left">. If you are unable to produce urine )anuria(.</p><p style="margin-left:116.55pt; text-align:left">. If you are treated with an artificial kidney.</p><p style="margin-left:121pt; margin-right:5.15pt; text-align:left; text-indent:-4.45pt">. If the level of potassium or sodium in your blood is lower than normal, or if the level of calcium in your blood is higher than normal despite treatment.</p><p style="margin-left:116.55pt; text-align:left">. If you have gout.</p><p style="margin-left:121pt; margin-right:0cm; text-align:left; text-indent:-4.45pt">. If you have diabetes or impaired kidney function and you are treated with a blood pressure lowering medicine called aliskiren.</p><p style="text-align:left">If any of the above applies to you, do not take this medicine and speak to your doctor. Take special care with Diostar-plus&reg; tablets</p><p style="margin-left:120.85pt; text-align:left; text-indent:-4.3pt">. If you are taking potassium-sparing medicines, potassium supplements, salt substitutes containing potassium or other medicines that increase the amount of potassium in your blood such as heparin. Your doctor may need to check the amount of potassium in your blood regularly.</p><p style="margin-left:116.55pt; text-align:left">. If you have low levels of potassium in your blood.</p><p style="margin-left:116.55pt; text-align:left">. If you have diarrhea or severe vomiting.</p><p style="margin-left:116.55pt; text-align:left">. If you are taking high doses of water tablets )diuretics(.</p><p style="margin-left:116.55pt; text-align:left">. If you have severe heart disease.</p><p style="margin-left:121pt; text-align:left; text-indent:-4.45pt">. If you are suffering from heart failure or have experienced a heart attack. Follow your doctor&rsquo;s instruction for the starting dose carefully. Your doctor may also check your kidney function.</p><p style="margin-left:116.55pt; text-align:left">. If you suffer from a narrowing of the kidney artery.</p><p style="margin-left:116.55pt; text-align:left">. If you have recently had a kidney transplant.</p><p style="margin-left:116.55pt; text-align:left">. If you suffer from hyperaldosteronism. This is a disease in which your adrenal glands make too much</p><p style="margin-left:120.75pt; text-align:left">of the hormone aldosterone. If this applies to you, the use of <strong>Diostar-plus</strong><strong>&reg;</strong><strong>&nbsp;</strong>tablets is not recom mended.</p><p style="margin-left:116.55pt; text-align:left">. If you have liver or kidney disease.</p><p style="margin-left:121pt; margin-right:5.15pt; text-align:left; text-indent:-4.45pt">. If you have ever experienced swelling of the tongue and face caused by an allergic reaction called angioedema when taking another drug )including ACE inhibitors(, tell your doctor. If these symp toms occur when you are taking <strong>Diostar-plus</strong><strong>&reg;</strong>, stop taking <strong>Diostar-plus</strong><strong>&reg; </strong>immediately and never take it again. See also section 4, &rdquo;Possible side effects&ldquo;.</p><p style="margin-left:121pt; margin-right:5.6pt; text-align:left; text-indent:-4.45pt">. If you have a fever, rash and joint pain, which may be signs of systemic lupus erythematosus )SLE, a so-called autoimmune disease(.</p><p style="margin-left:116.55pt; text-align:left">. If you have diabetes, gout, high levels of cholesterol or fats in your blood.</p><p style="margin-left:116.55pt; text-align:left">. If you have had allergic reactions with the use of other blood pressure-lowering agents of this class</p><p style="margin-left:121pt; text-align:left">)angiotensin II receptor antagonists( or if you have any allergies or asthma.</p><p style="margin-left:121pt; margin-right:0.4pt; text-align:left; text-indent:-4.45pt">. If you experience a decrease in vision or eye pain. These could be symptoms of an increase of&nbsp;&nbsp; pressure in your eye and can happen within hours to a week of taking <strong>Diostar-plus</strong><strong>&reg; </strong>this can lead to permanent vision loss, if not treated. If you earlier have had a penicillin or sulphonamide allergy you can be at higher risk of developing this.</p><p style="margin-left:116.55pt; text-align:left">. It may cause increased sensitivity of the skin to sun.</p><p style="margin-left:116.55pt; text-align:left">. The use of <strong>Diostar-plus</strong><strong>&reg; </strong>in children and adolescents below the age of 18 years is not recommended.</p><p style="margin-left:121pt; margin-right:2.35pt; text-align:left; text-indent:-4.45pt">. You must tell your doctor if you think you are )or might become( pregnant. <strong>Diostar-plus</strong><strong>&reg; </strong>is not recommended in early pregnancy, and must not be taken if you are more than 3 months pregnant, as it may cause serious harm to your baby if used at that stage )see pregnancy section(.</p><p style="margin-left:116.55pt; text-align:left">. if you are taking any of the following medicines used to treat high blood pressure:</p><p style="margin-left:121.35pt; text-align:left; text-indent:-2.55pt"><!--[if !supportLists]-->- <!--[endif]-->&rdquo;ACE inhibitors&ldquo; such as enalapril, lisinopril, etc</p><p style="margin-left:121.1pt; text-align:left; text-indent:-2.3pt"><!--[if !supportLists]-->- <!--[endif]-->Aliskiren</p><p style="text-align:left">If any of these apply to you, talk to your doctor. Taking other medicines</p><p style="margin-left:115.65pt; text-align:left">Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription.</p><p style="text-align:left">&nbsp;</p><p style="margin-left:115.65pt; margin-right:0.4pt; text-align:left">The effect of the treatment can be influenced if Valsartan/Hydrochlorothiazide tablets are taken together with certain other medicines. It may be necessary to change the dose, to take other precautions, or in some cases to stop taking one of the medicines.</p><p style="margin-left:115.65pt; text-align:left">This especially applies to the following medicines:</p><p style="margin-left:116.55pt; text-align:left">. Lithium, a medicine used to treat some types of psychiatric diseases.</p><p style="margin-left:120.95pt; margin-right:0cm; text-align:left; text-indent:-4.4pt">. Medicines or substances that may increase the amount of potassium in your blood. These include po tassium supplements or salt substitutes containing potassium, potassium-sparing medicines and heparin.</p><p style="margin-left:121pt; text-align:left; text-indent:-4.45pt">. Medicines that may reduce the amount of potassium in your blood, such as diuretics )water tablets(, corticosteroids, laxatives, carbenoxolone, amphotericin or penicillin G.</p><p style="margin-left:121pt; margin-right:2.35pt; text-align:left; text-indent:-4.45pt">. Some antibiotics )rifamycin group(, a drug used to protect against transplant rejection )ciclosporin(&nbsp;&nbsp; or an antiretroviral drug used to treat HIV/AIDS infection )ritonavir(. These drugs may increase the effect of <strong>Diostar-plus</strong><strong>&reg;</strong>.</p><p style="margin-left:116.55pt; text-align:left">. Medicines that may induce &rdquo;torsades de pointes&ldquo; )irregular heart beat(, such as antiarrhythmics</p><p style="margin-left:121pt; text-align:left">)medicines used to treat heart problems( and some antipsychotics.</p><p style="margin-left:121pt; margin-right:5.15pt; text-align:left; text-indent:-4.45pt">. Medicines that may reduce the amount of sodium in your blood, such as antidepressants, antipsy chotics, antiepileptics.</p><p style="margin-left:116.55pt; text-align:left">. Medicines for the treatment of gout, such as allopurinol, probenecid, sulfinpyrazone.</p><p style="margin-left:116.55pt; text-align:left">. Therapeutic vitamin D and calcium supplements</p><p style="margin-left:116.55pt; text-align:left">. Medicines for the treatment of diabetes )oral agents such as metformin or insulins(.</p><p style="margin-left:121pt; margin-right:5.15pt; text-align:left; text-indent:-4.45pt">. Other medicines to lower your blood pressure including methyldopa, ACE inhibitors )such as enalapril, lisinopril, etc.( or aliskiren.</p><p style="margin-left:116.55pt; text-align:left">. Medicines to increase blood pressure, such as noradrenaline or adrenaline.</p><p style="margin-left:116.55pt; text-align:left">. Digoxin or other digitalis glycosides )medicines used to treat heart problems(.</p><p style="margin-left:116.55pt; text-align:left">. Medicines that may increase blood sugar levels, such as diazoxide or beta blockers.</p><p style="margin-left:116.55pt; text-align:left">. Cytotoxic medicines )used to treat cancer(, such as methotrexate or cyclophosphamide.</p><p style="margin-left:121pt; margin-right:5.15pt; text-align:left; text-indent:-4.45pt">. Pain killers such as non-steroidal anti-inflammatory agents )NSAIDs(, including selective cyclooxy genase-2 inhibitors )Cox-2 inhibitors( and acetylsalicylic acid &gt; 3 g.</p><p style="margin-left:116.55pt; text-align:left">. Muscle relaxing medicines, such as tubocurarine.</p><p style="margin-left:121pt; margin-right:2.35pt; text-align:left; text-indent:-4.45pt">. anti-cholinergic medicines )medicines used to treat a variety of disorders such as gastrointestinal cramps, urinary bladder spasm, asthma, motion sickness, muscular spasms, Parkinson&rsaquo;s disease and as an aid to anaesthesia(.</p><p style="margin-left:121pt; margin-right:5.15pt; text-align:left; text-indent:-4.45pt">. Amantadine )medicine used to treat Parkinson&rsquo;s disease and also used to treat or prevent certain illnesses caused by viruses(.</p><p style="margin-left:116.55pt; text-align:left">. Cholestyramine and colestipol )medicines used mainly to treat high levels of lipids in the blood(.</p><p style="margin-left:116.55pt; text-align:left">. Ciclosporine, a medicine used for organ transplant to avoid organ rejection.</p><p style="margin-left:121pt; margin-right:5.15pt; text-align:left; text-indent:-4.45pt">. Alcohol, sleeping pills and anaesthetics )medicines with sleeping or painkilling effect used for example during surgery(.</p><p style="margin-left:116.55pt; text-align:left">. Iodine contrast media )agents used for imaging examinations(.</p><p style="text-align:left">Taking Diostar-plus&reg; tablets with food and drink</p><p style="margin-left:115.65pt; text-align:left">You can take <strong>Diostar-plus</strong><strong>&reg; </strong>tablets with or without food.</p><p style="margin-left:115.65pt; margin-right:3.8pt; text-align:left">Avoid taking alcohol until you have talked to your doctor. Alcohol may make your blood pressure fall too much and/or increase the risk of you becoming dizzy or feeling faint.</p><p style="text-align:left">Pregnancy and breast-feeding</p><p style="margin-left:115.65pt; text-align:left">Ask your doctor or pharmacist for advice before taking any medicine.</p><p style="text-align:left">You must tell your doctor if you think that you are (or might become( pregnant</p><p style="margin-left:115.65pt; margin-right:0.1pt; text-align:left">Your doctor will normally advise you to stop taking these tablets before you become pregnant or as soon as you know you are pregnant, and will advise you to take another medicine instead of <strong>Diostar-plus</strong><strong>&reg; </strong>tablets. <strong>Diostar-plus</strong><strong>&reg;&nbsp; </strong>tablets are not recommended in early pregnancy, and <strong>must not be taken when more than 3 months pregnant</strong>, as they may cause serious harm to your baby if they are used after the third month of pregnancy.</p><p style="text-align:left">Tell your doctor if you are breast-feeding or about to start breast-feeding</p><p style="margin-left:115.65pt; margin-right:0cm; text-align:left"><strong>Diostar-plus</strong><strong>&reg; </strong>tablets are not recommended for mothers who are breast-feeding, and your doctor may choose another treatment for you if you wish to breast-feed, especially if your baby is newborn, or was born prematurely.</p><p style="text-align:left">Driving and using machines</p><p style="margin-left:115.65pt; margin-right:-0.15pt; text-align:left">Before you drive a vehicle, use tools, operate machines, or carry out other activities that require concentra- tion, make sure you know how this medicine affects you. Like many other medicines used to treat high blood pressure <strong>Diostar-plus</strong><strong>&reg; </strong>tablets may in rare cases cause dizziness and affect the ability to concentrate.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="margin-right:2pt; text-align:left; text-indent:-0.05pt">Always take <strong>Diostar-plus</strong><strong>&reg; </strong>tablets exactly as your doctor has told you in order to get the best results&nbsp; and reduce the risk of side effects. You should check with your doctor or pharmacist if you are not sure. People with high blood pressure often do not notice any signs of this problem. Many may feel quite normal. This makes it all the more important for you to keep your appointments with your doctor even&nbsp; if you are feeling well.</p><p style="text-align:left">Your doctor will tell you exactly how many tablets to take. Depending on how you respond to the treat- ment, your doctor may suggest a higher or lower dose.</p><p style="text-align:left">. The usual dose is one tablet per day.</p><p style="text-align:left">. Do not change the dose or stop taking the tablets without consulting your doctor.</p><p style="text-align:left">. The medicine should be taken at the same time each day, usually in the morning.</p><p style="text-align:left">. You can take <strong>Diostar-plus</strong><strong>&reg; </strong><strong>tablets </strong>with or without food.</p><p style="text-align:left">. Swallow the tablet with a glass of water.</p><p style="text-align:left">If you take more Diostar-plus&reg; tablets than you should</p><p style="margin-right:0cm; text-align:left">If you experience severe dizziness and/or fainting, lie down and contact your doctor immediately. If you have accidentally taken too many tablets, contact your doctor, pharmacist or hospital.</p><p style="text-align:left">If you forget to take Diostar-plus&reg; tablets</p><p style="text-align:left">If you forget to take a dose, take it as soon as you remember.</p><p style="margin-right:48.2pt; text-align:left">However, if it is almost time for your next dose, skip the dose you missed. Do not take a double dose to make up for a forgotten dose.</p><p style="text-align:left">&nbsp;</p><p style="text-align:left">If you stop taking Diostar-plus&reg; tablets</p><p style="text-align:left">stopping your treatment with <strong>Diostar-plus</strong><strong>&reg; </strong>tablets may cause your high blood pressure to get worse. Do not stop taking your medicine unless your doctor tells you to.</p><p style="text-align:left">If you have any further questions on the use of this product, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="margin-left:12.1pt; margin-right:119.65pt; text-align:left">Like all medicines, <strong>Diostar-plus</strong><strong>&reg; </strong>tablets can cause side effects, although not everybody gets them. These side effects may occur with certain frequencies, which are defined as follows:</p><p style="margin-left:13pt; text-align:left">. Very common: affects more than 1 user in 10</p><p style="margin-left:13pt; text-align:left">. Common: affects 1 to 10 users in 100</p><p style="margin-left:13pt; text-align:left">. Uncommon: affects 1 to 10 users in 1,000</p><p style="margin-left:13pt; text-align:left">. Rare: affects 1 to 10 users in 10,000</p><p style="margin-left:13pt; text-align:left">. Very rare: affects less than 1 user in 10,000</p><p style="margin-left:13pt; text-align:left">. Not known: Frequency cannot be estimated from the available data</p><p style="text-align:left">Some side effects can be serious and need immediate medical attention:</p><p style="margin-left:12.1pt; margin-right:0cm; text-align:left">You should see your doctor immediately if you experience symptoms of angioedema, such as:</p><p style="margin-left:13pt; text-align:left">. swollen face, tongue or pharynx</p><p style="margin-left:13pt; text-align:left">. difficulty in swallowing</p><p style="margin-left:13pt; text-align:left">. hives and difficulties in breathing</p><p style="text-align:left">If you get any of these symptoms, stop taking Diostar-plus&reg; and contact your doctor straight away. (see also section 2 &ldquo;Take special care with Diostar-plus&reg; &rdquo;(.</p><p style="margin-left:12.1pt; margin-right:0cm; text-align:left"><strong>Other side effects which may occur:</strong></p><p style="margin-left:12.1pt; text-align:left"><strong>Uncommon:</strong></p><p style="margin-left:13pt; text-align:left">. cough</p><p style="margin-left:13pt; text-align:left">. low blood pressure</p><p style="margin-left:13pt; text-align:left">. light-headedness</p><p style="margin-left:17.4pt; margin-right:123pt; text-align:left; text-indent:-4.45pt">. dehydration )with symptoms of thirst, dry mouth and tongue, infrequent urination, dark colored urine, dry skin(</p><p style="margin-left:13pt; text-align:left">. muscle pain</p><p style="margin-left:13pt; text-align:left">. tiredness</p><p style="margin-left:13pt; text-align:left">. tingling or numbness</p><p style="margin-left:13pt; text-align:left">. blurred vision</p><p style="margin-left:13pt; text-align:left">. noises )e.g. hissing, buzzing( in ears</p><p style="text-align:left">Very rare:</p><p style="margin-left:13pt; text-align:left">. dizziness</p><p style="margin-left:13pt; text-align:left">. diarrhea</p><p style="margin-left:13pt; text-align:left">. Joint pain.</p><p style="text-align:left">Not known:</p><p style="margin-left:13pt; text-align:left">. breathing difficulty</p><p style="margin-left:13pt; text-align:left">. severely decreased urine output</p><p style="margin-left:17.4pt; margin-right:119.65pt; text-align:left; text-indent:-4.45pt">. low level of sodium in the blood )which can trigger tiredness, confusion, muscle twitching and /or convulsions in severe cases(</p><p style="margin-left:17.4pt; margin-right:119.65pt; text-align:left; text-indent:-4.45pt">. low level of potassium in the blood )sometimes with muscle weakness, muscle spasms, abnormal heart rhythm(</p><p style="margin-left:17.4pt; margin-right:119.65pt; text-align:left; text-indent:-4.45pt">. low level of white cells in the blood )with symptoms such as fever, skin infections, sore throat or mouth ulcers due to infections, weakness(</p><p style="margin-left:13pt; text-align:left">. the level of bilirubin increased in blood )which can, in severe cases, trigger yellow skin and eyes(</p><p style="margin-left:17.4pt; margin-right:119.65pt; text-align:left; text-indent:-4.45pt">. the level of blood urea nitrogen and creatinine increased in blood )which can indicate abnormal kidney function(</p><p style="margin-left:13pt; text-align:left">. the level of uric acid in blood increased )which can, in severe cases, trigger gout(</p><p style="margin-left:13pt; text-align:left">. syncope )fainting(</p><p style="text-align:left">The following side effects have been reported with products containing valsartan or hydrochlo- rothiazide alone.</p><p style="text-align:left"><strong>&nbsp;</strong></p><p style="margin-left:12.1pt; margin-right:269.75pt; text-align:left"><strong><u>Valsartan</u></strong><strong> Uncommon:</strong></p><p style="margin-left:13pt; text-align:left">. Spinning sensation</p><p style="margin-left:13pt; text-align:left">. Abdominal pain.</p><p style="text-align:left">Not known</p><p style="margin-left:17.4pt; margin-right:115.1pt; text-align:left; text-indent:-4.45pt">. skin rash with or without itching together with some of the following signs or symptoms: fever, joint pain, muscle pain, swollen lymph nodes and/or flu-like symptoms</p><p style="margin-left:13pt; text-align:left">. rash, purplish-red spots, fever, itching )symptoms of inflammation of blood vessels(</p><p style="margin-left:13pt; text-align:left">. low level of blood platelets )sometimes with unusual bleeding or bruising(</p><p style="margin-left:13pt; text-align:left">. high level of potassium in the blood )sometimes with muscle spasms, abnormal heart rhythm(</p><p style="margin-left:13pt; text-align:left">. allergic reactions )with symptoms such as rash, itching, hives, difficulty breathing or swallowing, dizziness(</p><p style="margin-left:13pt; text-align:left">. swelling mainly of the face and throat; rash; itching</p><p style="margin-left:13pt; text-align:left">. elevation of liver function values</p><p style="margin-left:17.4pt; margin-right:123pt; text-align:left; text-indent:-4.45pt">. The level of hemoglobin decreased and the percentage of red cells decreased in the blood )which both can, in severe cases, trigger anemia(.</p><p style="margin-left:13pt; text-align:left">. Kidney failure.</p><p style="margin-left:17.4pt; margin-right:119.65pt; text-align:left; text-indent:-4.45pt">. low level of sodium in the blood )which can trigger tiredness, confusion, muscle twitching and/or convulsions in severe cases(</p><p style="text-align:left">&nbsp;</p><p style="text-align:left"><u>Hydrochlorothiazid</u>e Very common:</p><p style="margin-left:13pt; text-align:left">. low level of potassium in the blood</p><p style="margin-left:13pt; text-align:left">. increase of lipids in the blood</p><p style="text-align:left">Common:</p><p style="margin-left:13pt; text-align:left">. low level of sodium in the blood</p><p style="margin-left:13pt; text-align:left">. low level of magnesium in the blood</p><p style="margin-left:13pt; text-align:left">. high level of uric acid in the blood</p><p style="margin-left:13pt; text-align:left">. itchy rash and other types of rash</p><p style="margin-left:13pt; text-align:left">. reduced appetite</p><p style="margin-left:13pt; text-align:left">. mild nausea and vomiting</p><p style="margin-left:13pt; text-align:left">. dizziness, fainting on standing up</p><p style="margin-left:13pt; text-align:left">. inability to achieve or maintain erection</p><p style="text-align:left">Rare:</p><p style="margin-left:13pt; text-align:left">. swelling and blistering of the skin )due to increased sensitivity to sun(</p><p style="margin-left:13pt; text-align:left">. high level of calcium in the blood</p><p style="margin-left:13pt; text-align:left">. high level of sugar in the blood</p><p style="margin-left:13pt; text-align:left">. sugar in the urine</p><p style="margin-left:13pt; text-align:left">. worsening of diabetic metabolic state</p><p style="margin-left:17.4pt; margin-right:123pt; text-align:left; text-indent:-4.45pt">. Constipation, diarrhea, discomfort of the stomach or bowels, liver disorders which can occur together with yellow skin or eyes.</p><p style="margin-left:13pt; text-align:left">. irregular heart beat</p><p style="margin-left:13pt; text-align:left">. headache</p><p style="margin-left:13pt; text-align:left">. sleep disturbances</p><p style="margin-left:13pt; text-align:left">. sad mood )depression(</p><p style="margin-left:13pt; text-align:left">. low level of blood platelets )sometimes with bleeding or bruising underneath the skin(.</p><p style="margin-left:13pt; text-align:left">. dizziness</p><p style="margin-left:13pt; text-align:left">. tingling or numbness</p><p style="margin-left:13pt; text-align:left">. vision disorder</p><p style="text-align:left">Very rare:</p><p style="margin-left:13pt; text-align:left">. inflammation of blood vessels with symptoms such as rash, purplish-red spots, fever )vasculitis(</p><p style="margin-left:13pt; text-align:left">. rash, itching, hives, difficulty breathing or swallowing, dizziness )hypersensitivity reactions(</p><p style="margin-left:17.4pt; margin-right:123pt; text-align:left; text-indent:-4.45pt">. severe skin disease that causes rash, red skin, blistering of the lips, eyes or mouth, skin peeling, fever )toxic epidermal necrolysis(</p><p style="margin-left:13pt; text-align:left">. facial rash, joint pain, muscle disorder, fever )lupus erythematosus(</p><p style="margin-left:13pt; text-align:left">. severe upper stomach pain )pancreatitis(</p><p style="margin-left:17.4pt; margin-right:119.65pt; text-align:left; text-indent:-4.45pt">. difficulty breathing with fever, coughing, wheezing, breathlessness )respiratory distress including pneumonitis and pulmonary oedema(</p><p style="margin-left:13pt; text-align:left">. fever, sore throat, more frequent infections )agranulocytosis(</p><p style="margin-left:13pt; text-align:left">. pale skin, tiredness, breathlessness, dark urine )haemolytic anaemia(</p><p style="margin-left:13pt; text-align:left">. fever, sore throat or mouth ulcers due to infections )leucopenia(</p><p style="margin-left:13pt; text-align:left">. confusion, tiredness, muscle twitching and spasm, rapid breathing )hypochloraemic alkalosis(</p><p style="text-align:left">Not known:</p><p style="margin-left:13pt; text-align:left">. weakness, bruising and frequent infections )aplastic anemia(</p><p style="margin-left:13pt; text-align:left">. severely decreased urine output )possible signs of renal disorder or renal failure(</p><p style="margin-left:13pt; text-align:left">. decrease in vision or pain in your eyes due to high pressure )possible signs of acute angle-closure glaucoma(</p><p style="margin-left:13pt; text-align:left">. rash, red skin, blistering of the lips, eyes or mouth, skin peeling, fever )possible signs of erythema multiform(</p><p style="margin-left:13pt; text-align:left">. muscle spasm</p><p style="margin-left:13pt; text-align:left">. fever )pyrexia(</p><p style="margin-left:13pt; text-align:left">. weakness )asthenia(</p><p style="text-align:left">If any of the side effects get serious or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="margin-left:12.1pt; text-align:left">Keep out of the reach and sight of children.</p><p style="margin-left:12.1pt; margin-right:123pt; text-align:left">Do not use <strong>Diostar-plus</strong><strong>&reg; </strong>after the expiry date )EXP( which is stated on the blister and the carton. The expiry date refers to the last day of that month.</p><p style="margin-left:12.1pt; margin-right:115.1pt; text-align:left"><strong>Diostar-plus</strong><strong>&reg; </strong>tablets: Store below 30&deg;C. Store in the original package in order to protect from moisture Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="margin-left:12.1pt; text-align:left">The active substances are valsartan and hydrochlorothiazide.</p><p style="margin-left:12.1pt; margin-right:115.1pt; text-align:left">The other ingredients are Microcrystalline cellulose, Croscarmellose sodium, Povidone K30, Colloidal silicon dioxide, Magnesium stearate, Opadry OY-L, FD&amp;C red # 40, FD&amp;C blue # 1.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Diostar-plus® 160 mg/12.5 mg
Purple oblong deep biconvex film coated tablet, scored on one face & engraved with PhI on the other, packed in Alu/Alu blister, intended for oral use.
Pack size: 30 tablets (10 tablets / blister, 3 blister / pack)

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="margin-left:12.1pt; margin-right:239.2pt; text-align:left">Pharma International Company Amman - Jordan</p><p style="margin-left:12.1pt; text-align:left">Tel: 00962-6-5158890 / 5157893</p><p style="margin-left:12.1pt; text-align:left">Fax: 00962-6-5154753</p><p style="margin-left:12.1pt; text-align:left">Email: marketing@pic-jo.com</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in 10/2015
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p style="margin-left:0cm" dir="RTL"><strong>ديوستار</strong><strong>- بلص</strong><strong>&reg;</strong>&nbsp;أقراص مغلفة بفيلم تحتوي على نوعين من المواد الفعالة و هي ڤالسارتان وهيدروكلوروثيازيد.</p><p style="margin-left:0cm" dir="RTL">كل من هذه المواد تساعد في السيطرة على ارتفاع ضغط الدم .</p><p style="margin-left:0cm; margin-right:40px" dir="RTL"><strong>&bull; ڤالسارتان</strong><strong>:</strong> ينتمي الى مجموعة من الادوية تعرف بإسم مضادات مستقبالت الانجيوتنسينII ، والتي تساعد في السيطرة على ارتفاع</p><p style="margin-left:0cm; margin-right:40px" dir="RTL">ضغط الدم. أنجيوتنسين II هي عبارة عن مادة في الجسم تسبب تضييق في الاوعية الدموية، مما يؤدي إلى ارتفاع ضغط الدم. يعمل</p><p style="margin-left:0cm; margin-right:40px" dir="RTL">ڤالسارتان عن طريق منع تأثير أنجيوتنسين . II ونتيجة لذلك، تسترخي الاوعية الدموية وينخفض ضغط الدم.</p><p style="margin-left:0cm; margin-right:40px" dir="RTL">&bull;<strong> هيدروكلوروثيازيد</strong>: ينتمي إلى مجموعة من الادوية تعرف بإسم مدرات البول الثيازيدية (المعروف أيضا باسم &ldquo;أقراص الماء&rdquo; .)</p><p style="margin-left:0cm; margin-right:40px" dir="RTL">هيدروكلوروثيازيد يزيد من إخراج البول، مما يعمل أيضا على خفض ضغط الدم.</p><p>يستخدم ديوستار- بلص&reg;&nbsp;أقراص لعلاج ارتفاع ضغط الدم الذي لا تتم السيطرة عليه بشكل كاف عن طريق مادة فعالة واحدة</p><p style="margin-left:14.45pt; text-indent:4.05pt" dir="RTL">ارتفاع ضغط الدم يزيد من عبء العمل على القلب والشرايين. إذا لم يتم عالجه، فإنه يمكن أن يتلف الاوعية الدموية في الدماغ والقلب، والكلى، ويمكن أن يؤدي سكتة دماغية، وفشل القلب أو الكلى. ارتفاع ضغط الدم يزيد من مخاطر الاصابة بأزمات قلبية. خفض ضغط الدم إلى وضعه الطبيعي يقلل من خطر الاصابة بهذه الاضطرابات.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p style="margin-left:0cm" dir="RTL"><strong>ا</strong><strong>لحالات</strong><strong> التي يجب أن لا تأخذ فيها ديوستار</strong><strong>-</strong><strong> </strong><strong>بل</strong><strong>ص</strong><strong>&reg;</strong><strong>&nbsp;</strong><strong>أقرا</strong><strong>ص</strong><strong>:</strong></p><p style="margin-left:0cm; margin-right:40px" dir="RTL">&bull; إذا كنت تعاني من تحسس (حساسية مفرطة) لڤالسارتان، أو هيدروكلوروثيازيد، أو مشتقات السلفونيمايد (المواد المرتبطة كيميائيا</p><p style="margin-left:0cm; margin-right:40px" dir="RTL">بالهيدروكلوروثيازيد) أو أي من المكونات الاخرى لهذه الاقراص.</p><p style="margin-left:0cm; margin-right:40px" dir="RTL">&bull; إذا كنت حامل لأكثر من 3 أشهر (من الافضل أيضا تجنب أقراص ڤالسارتان / هيدروكلوروثيازيد في مراحل الحمل المبكرة- انظر بند</p><p style="margin-left:0cm; margin-right:40px" dir="RTL">&ldquo;الحمل والرضاعة الطبيعية)&rdquo;</p><p style="margin-left:0cm; margin-right:40px" dir="RTL">&bull; إذا كنت تعاني من مرض حاد في الكبد، أو تهتك في قنوات الصفراء داخل الكبد (التشمع الصفراوي) مما يؤدي إلى تراكم الصفراء في</p><p style="margin-left:0cm; margin-right:40px" dir="RTL">الكبد (الركود الصفراوي.)</p><p style="margin-left:0cm; margin-right:40px" dir="RTL">&bull; إذا كنت تعاني من مرض حاد في الكلى</p><p style="margin-left:0cm; margin-right:40px" dir="RTL">&bull; إذا كنت غير قادر على افراز البول</p><p style="margin-left:0cm; margin-right:40px" dir="RTL">&bull; إذا كان يتم علاجك بالكلى الاصطناعية</p><p style="margin-left:0cm; margin-right:40px" dir="RTL">&bull; إذا كان مستوى البوتاسيوم أو الصوديوم في الدم أقل من المعتاد، أو إذا كان مستوى الكالسيوم في الدم أعلى من المعتاد على الرغم</p><p style="margin-left:0cm" dir="RTL">من العلاج</p><p style="margin-left:0cm; margin-right:40px" dir="RTL">&bull; إذا كنت تعاني من النقرس</p><p style="margin-left:0cm; margin-right:40px" dir="RTL">&bull; إذا كنت تعاني من مرض السكري أو اختلال في وظائف الكلى ويتم عالجك لخفض ضغط الدم باستخدام دواء يسمى أليسكيرين</p><p>&nbsp;</p><p>إذا كان أي مما ذكر أعلاه ينطبق عليك، لا تتناول هذا الدواء و راجع طبيبك.</p><p style="margin-left:0cm" dir="RTL"><strong>اتخذ</strong><strong> احتياطات خاصة مع ديوستار</strong><strong>-</strong><strong> </strong><strong>بل</strong><strong>ص</strong><strong>&reg;</strong><strong>&nbsp;</strong><strong>أقرا</strong><strong>ص</strong></p><p style="margin-left:0cm; margin-right:40px" dir="RTL">&bull; إذا كنت تأخذ الادوية التي تقتصد البوتاسيوم، مكملات البوتاسيوم، وبدائل الملح التي تحتوي على البوتاسيوم أو غيرها من الادوية التي تزيد من كمية البوتاسيوم في الدم مثل الهيبارين. قد يحتاج طبيبك للتحقق من كمية البوتاسيوم في الدم بانتظام.</p><p style="margin-left:0cm; margin-right:40px" dir="RTL">&bull; إذا كان لديك مستويات منخفضة من البوتاسيوم في الدم.</p><p style="margin-left:0cm; margin-right:40px" dir="RTL">&bull; إذا كنت تعاني من الاسهال أو القيء الشديد.</p><p style="margin-left:0cm; margin-right:40px" dir="RTL">&bull; إذا كنت تأخذ جرعات عالية من أقراص الماء (مدرات البول.)</p><p style="margin-left:0cm; margin-right:40px" dir="RTL">&bull; إذا كان لديك أمراض خطيرة في القلب.</p><p style="margin-left:0cm; margin-right:40px" dir="RTL">&bull; إذا كنت تعاني من قصور في القلب أو تعرضت لنوبة قلبية. اتبع تعليمات طبيبك بشأن الجرعة الابتدائية بعناية. قد يحتاج طبيبك إلى التحقق من وظيفة الكلى لديك.</p><p style="margin-left:0cm; margin-right:40px" dir="RTL">&bull; إذا كنت تعاني من تضيق الشريان الكلوي.</p><p style="margin-left:0cm; margin-right:40px" dir="RTL">&bull; إذا خضعت في الآونة الأخيرة لعملية زرع الكلى.</p><p style="margin-left:0cm; margin-right:40px" dir="RTL">&bull; إذا كنت تعاني من فرط إفراز الألدوستيرون. هذ المرض الذي تفرز فيه الغدد الكظرية لديك كميات أكبر من الطبيعي من هرمون الألدوستيرون. إذا كان هذا ينطبق عليك، فمن غير المستحسن ان تستخدم أقراص<strong> ديوستار</strong><strong>- بلص</strong>.<strong>&reg;</strong></p><p style="margin-left:0cm; margin-right:40px" dir="RTL">&bull; إذا كان لديك مرض في الكبد أو الكلى.</p><p style="margin-left:20.95pt; text-indent:-4.45pt" dir="RTL">&bull; إذا كان قد سبق أن تعرضت لتورم في اللسان والوجه نتيجة رد فعل تحسسي ( وذمة وعائية) عند اخذ دواء آخر (بما في ذلك مثبطات )ACE،فعليك أخبار طبيبك. في حالة حدوث هذه الأعراض عند أخذك أقراص<strong> ديوستار</strong><strong>- بلص</strong><strong>&reg;</strong>&nbsp;فعليك التوقف عن أخذ هذا الدواء فوراً&nbsp;و عدم أخذه مرة أخرى. انظر أيضا الباب 4، &ldquo;الآثار الجانبية المحتملة.&rdquo;</p><p style="margin-left:0cm; margin-right:40px" dir="RTL">&bull; إذا كان لديك حمى وطفح جلدي وآلام في المفاصل، والتي قد تكون علامات الذئبة الحمامية الجهازية ( وهو من أمراض المناعة الذاتية.)</p><p style="margin-left:0cm; margin-right:40px" dir="RTL">&bull; إذا كان لديك مرض السكري، والنقرس، وارتفاع مستويات الكوليسترول أو الدهون في الدم.</p><p style="margin-left:0cm; margin-right:40px" dir="RTL">&bull; إذا سبق أن حصل لديك حساسية مع استخدام أدوية أخرى لخفض ضغط الدم من هذه الفئة (مستقبلات أنجيوتنسين )II أو إذا كان لديك أي حساسية أو الربو.</p><p style="margin-left:15.5pt; text-indent:-1.9pt" dir="RTL">&bull; إذا شعرت بضعف في الرؤية أو ألم في العينين. هذه عادة ما تكون أعراض زيادة الضغط في العين ويمكن أن يحدث خلال ساعات لمدة أسبوع من استخدام أقراص<strong> ديوستار</strong><strong>- بلص</strong><strong>&reg;&nbsp;</strong><strong>.</strong> قد يؤدي هذا إلى فقدان الرؤية بشكل دائم&nbsp; إذا لم يتم عالجه. إذا كنت قد اصبت في وقت سابق بحساسية للبنسلين أو السيفالوسبورينات، فأنت أكثر عرضة لتطوير هذا العرض.</p><p style="margin-left:0cm; margin-right:40px" dir="RTL">&bull; قد يسبب استخدام هذا الدواء زيادة حساسية الجلد لأشعة الشمس.</p><p style="margin-left:0cm; margin-right:40px" dir="RTL">&bull; لا ينصح باستخدام أقراص<strong> ديوستار</strong><strong>- بلص</strong><strong>&reg;</strong>&nbsp;في الاطفال والمراهقين دون سن 18 عاما.</p><p style="margin-left:0cm; margin-right:40px" dir="RTL">&bull; يجب إخبار الطبيب إذا كنت تعتقدين أنك (أو قد تصبحين) حاملا. لا ينصح&nbsp; باستخدام<strong> ديوستار</strong><strong>- بلص</strong><strong>&reg;</strong>&nbsp;في مراحل الحمل المبكرة ، كما</p><p dir="RTL">ويجب ألا يؤخذ إذا كان الحمل أكثر من 3 أشهر لانه قد يسبب ضرراََ&nbsp;جسيماََ&nbsp;لطفلك إذا ما استخدم في تلك المرحلة (انظر قسم الحمل.)</p><p style="margin-left:118.05pt; margin-right:40px; text-indent:-27.85pt" dir="RTL">&bull; إذا كنت تأخذ أي من الادوية التالية التي تستخدم لعلاج ارتفاع ضغط الدم: <strong>-</strong> &ldquo;مثبطات &rdquo;ACE مثل إنالابريل، ليسينوبريل، الخ</p><p style="margin-left:0cm; margin-right:40px" dir="RTL"><strong>-</strong> أليسكيرين</p><p>إذا كان أي مما ذكر أعلاه ينطبق عليك، تحدث إلى طبيبك.</p><p style="margin-left:0cm" dir="RTL"><strong>تناول أدوية أخرى</strong></p><p style="margin-left:0cm" dir="RTL">يرجى إخبار الطبيب أو الصيدلي إذا كنت تأخذ أو اخذت مؤخرا أية أدوية أخرى، بما في ذلك الأدوية التي يمكن الحصول عليها دون وصفة طبية. قد تتأثر النتيجة العلاجية إذا ما اخذت أقراص ڤالسارتان / هيدروكلوروثيازيد جنبا إلى جنب مع بعض الأدوية الأخرى. قد يكون من الضروري تغيير الجرعة،أو اتخاذ احتياطات أخرى، أو في بعض الحالات إلى التوقف عن أخذ واحد من الأدوية.</p><p style="margin-left:0cm" dir="RTL">هذا ينطبق بشكل خاص على الادوية التالية:</p><p style="margin-left:0cm; margin-right:40px" dir="RTL">&bull; الليثيوم، وهو دواء يستخدم لعلاج بعض أنواع الأمراض النفسية.</p><p style="margin-left:0cm; margin-right:40px" dir="RTL">&bull; الأدوية أو المواد التي قد تزيد من كمية البوتاسيوم في الدم. وتشمل هذه مكملات البوتاسيوم أو بدائل الملح التي تحتوي على البوتاسيوم،</p><p style="margin-left:0cm; margin-right:40px" dir="RTL">والأدوية التي تقتصد البوتاسيوم والهيبارين.</p><p style="margin-left:0cm; margin-right:40px" dir="RTL">&bull; الأدوية التي قد تقلل من كمية البوتاسيوم في الدم، مثل مدرات البول (أقراص الماء)، والاستيرويدات القشرية، الملينات، كربينوكسولون،</p><p style="margin-left:0cm; margin-right:40px" dir="RTL">الامفوتريسين أو البنسلين .G</p><p style="margin-left:0cm" dir="RTL">&bull; بعض المضادات الحيوية (مجموعة ريفاميسن)، وهو دواء يستخدم لمنع الجسم من رفض الزرع ،(سيكلوسبورين) أو الدواء المضاد للفيروسات القهقرية والمستخدم لعلاج العدوى بفيروس نقص المناعة البشرية / الإيدز (ريتونافير.) هذه الادوية قد يزيد من تأثير<strong> ديوستار</strong><strong>-</strong><strong>بلص</strong>.<strong>&reg;</strong></p><p style="margin-left:0cm; margin-right:40px" dir="RTL">&bull; الادوية التي ربما تسبب عدم انتظام ضربات القلب، مثل (الادوية المستخدمة لعلاج مشاكل القلب) وبعض مضادات الذهان.</p><p style="margin-left:0cm; margin-right:40px" dir="RTL">&bull;الادوية التي قد تقلل من كمية الصوديوم في الدم، مثل مضادات الاكتئاب، مضادات الذهان، مضادات الصرع.</p><p style="margin-left:0cm; margin-right:40px" dir="RTL">&bull; أدوية عالج النقرس، مثل اللوبيورينول، البروبينسيد، سلفينبيرازون.</p><p style="margin-left:0cm; margin-right:40px" dir="RTL">&bull; فيتامين D العلاجي والكالسيوم.</p><p style="margin-left:0cm; margin-right:40px" dir="RTL">&bull; أدوية علاج مرض السكري (مثل الميتفورمين أو الانسولين.)</p><p style="margin-left:0cm; margin-right:40px" dir="RTL">&bull; أدوية أخرى لخفض ضغط الدم بما في ذلك ميثيل دوبا، مثبطات ACE (مثل إنالابريل، ليسينوبريل، الخ) أو أليسكيرين.</p><p style="margin-left:0cm; margin-right:40px" dir="RTL">&bull; الأدوية لزيادة ضغط الدم، مثل النورأدرينالين أو الادرينالين.</p><p style="margin-left:0cm; margin-right:40px" dir="RTL">&bull; الديجوكسين أو جليكوسيدات الديجيتال الاخرى (الادوية المستخدمة لعلاج مشاكل القلب.)</p><p style="margin-left:0cm; margin-right:40px" dir="RTL">&bull; الادوية التي قد تزيد من مستويات السكر في الدم، مثل ديازوكسيد أو حاصرات بيتا.</p><p style="margin-left:0cm; margin-right:40px" dir="RTL">&bull; الادوية السامة للخلايا (التي تستخدم لعلاج السرطان)، مثل الميثوتركسات أو سيكلوفوسفاميد.</p><p style="margin-left:0cm; margin-right:40px" dir="RTL">&bull; مسكنات الآلام مثل&nbsp; مضادة الالتهابات غير الستيرويدية ، بما في ذلك مثبطات انزيمات الاكسدة الحلقية2- الانتقائية (مثبطات&nbsp; )COX-2 وحامض السيليسيليك (أكثر من 3 غرام.)</p><p style="margin-left:0cm; margin-right:40px" dir="RTL">&bull; الادوية المرخية للعضلات ، مثل توبوكيورارين.</p><p style="margin-left:0cm; margin-right:40px" dir="RTL">&bull; &nbsp;الادوية المضادة للكولين (الادوية المستخدمة لعلاج مجموعة متنوعة من الاضطرابات مثل تقلصات المعدة والامعاء، تشنج المثانة البولية ،</p><p style="margin-left:0cm; margin-right:40px" dir="RTL">والربو، ودوار الحركة، وتشنجات العضلات، ومرض باركنسون وكعامل مساعد في التخدير.)</p><p style="margin-left:0cm; margin-right:40px" dir="RTL">&bull; أمانتادين (دواء يستخدم لعلاج مرض باركنسون وأيضا يستخدم لعلاج أو منع بعض الأمراض التي تسببها الفيروسات.)</p><p style="margin-left:0cm; margin-right:40px" dir="RTL">&bull; الكولسترامين وكوليستيبول (أدوية تستخدم أساسا لعلاج ارتفاع مستويات الدهون في الدم.)</p><p style="margin-left:0cm; margin-right:40px" dir="RTL">&bull; سيكلوسبورين، وهو دواء يستخدم لزرع الأعضاء لتجنب رفض العضو.</p><p style="margin-left:0cm; margin-right:40px" dir="RTL">&bull; الكحول، الحبوب المنومة و أدوية التخدير المستخدمة أثناء الجراحة.</p><p style="margin-left:0cm; margin-right:40px" dir="RTL">&bull; المواد الغنية باليود لغايات التصوير االشعاعي.</p><p>أخذ أقراص ديوستار- بلص&reg;&nbsp;مع الطعام والشراب</p><p>يمكنك أن تأخذ أقراص<strong> ديوستار</strong><strong>- بلص</strong><strong>&reg;</strong>&nbsp;مع أو بدون الطعام. تجنب تناول الكحول لحين تحدثك إلى الطبيب. الكحول قد يجعل ضغط الدم ينخفض أكثر من اللازم&nbsp; و / أو يزيد من خطر اصابتك بالدوار</p><p style="margin-left:0cm" dir="RTL">أو الشعور بالإغماء.</p><p>الحمل والرضاعة الطبيعية</p><p style="margin-left:0cm" dir="RTL">إسألي طبيبك أو الصيدلي للحصول على المشورة قبل أن تأخذي أي دواء.</p><p style="margin-left:0cm" dir="RTL">يجب إخبار الطبيب إذا كنت تعتقدين أنك حامل أو قد تصبحين حامل. سوف ينصحك طبيبك بالتوقف عن تناول هذه الاقراص قبل أن تصبحي حاملا أو حالما تعلمين انك حامل، وسينصحك بأخذ دواء بديل</p><p style="margin-left:0cm" dir="RTL">عن<strong> ديوستار</strong><strong>-</strong><strong> </strong><strong>بل</strong><strong>ص</strong><strong>&reg;</strong>&nbsp;. لا ينصح بأخذ أقراص<strong> ديوستار</strong><strong>-</strong><strong> </strong><strong>بل</strong><strong>ص</strong><strong>&reg;</strong>&nbsp;في المراحل المبكرة من الحمل، ويجب ألا تؤخذ بعد مرور 3 أشهر من الحمل، لأنها قد تسبب ضررا خطيرا لطفلك إذا تم استخدامها بعد الشهر الثالث من الحمل.</p><p>أخبري طبيبك إذا كنت تُرضعين رضاعة طبيعية أو على وشك أن تبدئي بالإرضاع طبيعياََ.</p><p style="margin-left:0cm" dir="RTL">لا ينصح باستخدام أقراص<strong> ديوستار</strong><strong>- بلص</strong><strong>&reg;</strong>&nbsp; للأمهات المرضعات، و قد يختار الطبيب دواء آخر لك إذا كنت ترغبين في الارضاع،</p><p style="margin-left:0cm" dir="RTL">وخاصة إذا كان طفلك حديث الوالدة، أو ولد قبل الأوان.</p><p style="margin-left:0cm" dir="RTL"><strong>القيادة واستخدام اآلالت</strong></p><p style="margin-left:0cm" dir="RTL">قبل أن تقود السيارة، أو تستخدم الأدوات أو تشغل الآلات ، أو تنفذ أية أنشطة أخرى تتطلب التركيز، تأكد من أنك تعرف كيف سيؤثر هذا الدواء عليك. مثل العديد من الأدوية الأخرى المستخدمة لعلاج ارتفاع ضغط الدم أقراص<strong> ديوستار</strong><strong>- بلص</strong><strong>&reg;</strong>&nbsp;&nbsp;قد تسبب في حالات نادرة الدوخة وتؤثر على القدرة على التركيز.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p style="margin-left:0cm; text-align:right" dir="RTL">تناول أقراص<strong> ديوستار</strong><strong>- بلص</strong><strong>&reg;</strong>&nbsp;&nbsp;دائما كما أخبرك طبيبك ، من أجل الحصول على أفضل النتائج وتقليل خطر الآثار الجانبية. يجب عليك التحقق مع طبيبك أو الصيدلي إذا لم تكن متأكدا من كيفية استخدام الدواء. إن الأشخاص الذين يعانون من ارتفاع ضغط الدم في كثير من الأحيان لا يلاحظون أي من علامات هذه المشكلة. قد يشعر الكثيرون بأن وضعهم طبيعي جدا. وهذا يجعل الأمر أكثر أهمية بالنسبة لك للحفاظ على مواعيدك مع طبيبك حتى لو كنت على ما يرام.</p><p style="margin-left:0cm; text-align:right" dir="RTL">طبيبك سوف يخبرك بالضبط عن عدد الأقراص اللازمة لك. اعتمادا على كيفية استجابتك للعلاج، قد يقترح الطبيب جرعة أعلى أو أدنى.</p><p style="margin-left:0cm; margin-right:40px; text-align:right" dir="RTL">&bull; الجرعة المعتادة هي قرص واحد يوميا.</p><p style="margin-left:0cm; margin-right:40px; text-align:right" dir="RTL">&bull; لا تغيّر الجرعة أو تتوقف عن تناول الأقراص دون استشارة الطبيب.</p><p style="margin-left:0cm; margin-right:40px; text-align:right" dir="RTL">&bull; ينبغي أن يؤخذ هذا الدواء في نفس الوقت كل يوم، وعادة في الصباح.</p><p style="margin-left:0cm; margin-right:40px; text-align:right" dir="RTL">&bull; يمكنك تناول أقراص<strong> ديوستار</strong><strong>-</strong><strong> </strong><strong>بل</strong><strong>ص</strong><strong>&reg;</strong>&nbsp; مع أو بدون الطعام.</p><p style="margin-right:40px; text-align:right" dir="RTL">&bull; ابتلع القرص كاملا مع كوب من الماء.</p><p>إذا كنت تأخذ عدداً&nbsp;أكبر من أقراص ديوستار- بلص&reg;&nbsp; مما يجب إذا شعرت بدوخة شديدة و / أو إغماء، استلق واتصل بطبيبك على الفور. إذا كنت قد اخذت عن طريق الخطأ الكثير من أقراص<strong> ديوستار</strong><strong>-</strong></p><p style="margin-left:0cm; text-align:right" dir="RTL"><strong>بلص</strong><strong>&reg;</strong>&nbsp;، اتصل بطبيبك أو الصيدلي أو المستشفى.</p><p>إذا كنت قد نسيت أن تأخذ أقراص ديوستار- بلص&reg;</p><p style="margin-left:0cm; text-align:right" dir="RTL">إذا كنت قد نسيت أن تأخذ جرعة، خذها حالما تتذكرها، ومع ذلك، إذا كان الوقت قارب على موعد تناول الجرعة التالية فتجاوز الجرعة</p><p style="margin-left:0cm; text-align:right" dir="RTL">التي فاتتك.</p><p style="margin-left:0cm; text-align:right" dir="RTL">لا تأخذ جرعة مضاعفة لتعويض الجرعة المنسية.</p><p>&nbsp;</p><p>إذا توقفت عن أخذ أقراص ديوستار- بلص&reg; قد يسبب التوقف عن أخذ أقراص<strong> ديوستار</strong><strong>- بلص</strong><strong>&reg;</strong>&nbsp;&nbsp;ازدياد حالة ارتفاع ضغط الدم لديك سوءاً. لا تتوقف عن أخذ الدواء ما لم يخبرك طبيبك بذلك.</p><p>إذا كان لديك أية أسئلة أخرى عن استخدام هذا الدواء، اسأل طبيبك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p style="text-align:right" dir="RTL">مثل جميع األدوية، يمكن لأقراص<strong> ديوستار</strong><strong>- بلص</strong><strong>&reg;</strong>&nbsp;&nbsp;أن تتسبب في آثار جانبية، على الرغم من أنها لا تحصل&nbsp; عند الجميع.</p><p style="margin-left:0cm; margin-right:.05pt; text-align:right" dir="RTL">قد تحدث هذه الآثار الجانبية حسب ترددات معينة، كما يلي:</p><p style="margin-left:0cm; margin-right:1.9pt; text-align:right" dir="RTL">&bull; شائعة جدا: تؤثر على أكثر من مستخدم 1 من كل 10 مستخدمين</p><p style="margin-left:0cm; margin-right:1.95pt; text-align:right" dir="RTL">&bull; شائعة: تؤثر على 1 إلى 10 من كل 100 مستخدم</p><p style="margin-left:0cm; margin-right:1.95pt; text-align:right" dir="RTL">&bull; غير شائعة: تؤثر على 1 إلى 10 من كل 1000 مستخدم</p><p style="margin-left:0cm; margin-right:1.95pt; text-align:right" dir="RTL">&bull; نادرة: تؤثر على 1 إلى 10 من كل 10000 مستخدم</p><p style="margin-left:0cm; margin-right:1.95pt; text-align:right" dir="RTL">&bull; نادرة جدا: تؤثر على أقل من مستخدم 1 من كل 10000 مستخدم</p><p style="margin-left:0cm; margin-right:1.95pt; text-align:right" dir="RTL">&bull; غير معروفة: التردد لا يمكن أن يقدر من البيانات المتاحة</p><p style="margin-left:0cm; margin-right:1.95pt; text-align:right" dir="RTL">بعض الآثار الجانبية يمكن أن تكون خطيرة وتحتاج إلى عناية طبية فورية:</p><p style="margin-left:0cm; margin-right:.05pt; text-align:right" dir="RTL">يجب مراجعة الطبيب فورا إذا واجهت أعراض وذمة وعائية، مثل:</p><p style="margin-left:0cm; margin-right:1.95pt; text-align:right" dir="RTL">&bull; تورم الوجه واللسان أو البلعوم</p><p style="margin-left:0cm; margin-right:1.95pt; text-align:right" dir="RTL">&bull; صعوبة في البلع</p><p style="margin-left:0cm; margin-right:1.95pt; text-align:right" dir="RTL">&bull; شري وصعوبات في التنفس</p><p>اذا كان لديك أي من هذه الأعراض، توقف عن أخذ ديوستار- بلص&reg;&nbsp; واتصل بطبيبك على الفور.</p><p style="margin-left:0cm; margin-right:.05pt; text-align:right" dir="RTL"><strong>(</strong><strong>انظر</strong><strong> أيضا القسم </strong><strong>2</strong><strong> </strong><strong>(</strong><strong>عناية</strong><strong> خاصة عند استخدام ديوستار</strong><strong>-</strong><strong> </strong><strong>بل</strong><strong>ص</strong><strong>.)</strong><strong>&reg;</strong></p><p style="text-align:right" dir="RTL"><strong>الآثار الجانبية الأخرى التي قد تحدث</strong><strong>:</strong></p><p style="text-align:right" dir="RTL"><strong>غير شائعة</strong><strong>:</strong></p><p style="margin-left:0cm; margin-right:1.95pt; text-align:right" dir="RTL">&bull; السعال</p><p style="margin-left:0cm; margin-right:1.95pt; text-align:right" dir="RTL">&bull; انخفاض ضغط الدم</p><p style="margin-left:0cm; margin-right:1.95pt; text-align:right" dir="RTL">&bull; الدوخة</p><p style="margin-left:0cm; margin-right:1.9pt; text-align:right" dir="RTL">&bull; الجفاف (مع أعراض العطش وجفاف الفم واللسان، والتبول غير المنتظم والبول داكن اللون، وجفاف الجلد)</p><p style="margin-left:0cm; margin-right:1.95pt; text-align:right" dir="RTL">&bull; آلام في العضلات</p><p style="margin-left:0cm; margin-right:1.95pt; text-align:right" dir="RTL">&bull; التعب</p><p style="margin-left:0cm; margin-right:1.95pt; text-align:right" dir="RTL">&bull; وخز أو خدر</p><p style="margin-left:0cm; margin-right:1.95pt; text-align:right" dir="RTL">&bull; عدم وضوح الرؤية</p><p style="margin-left:0cm; margin-right:1.9pt; text-align:right" dir="RTL">&bull; الضوضاء (مثل الهسهسة، و الطنين) في الأذنين</p><p>نادرة جدا:</p><p style="margin-left:0cm; margin-right:1.95pt; text-align:right" dir="RTL">&bull; الدوخة</p><p style="margin-left:0cm; margin-right:1.95pt; text-align:right" dir="RTL">&bull; الإسهال</p><p style="margin-left:0cm; margin-right:1.95pt; text-align:right" dir="RTL">&bull; آلآم المفاصل.</p><p>غير معروفة:</p><p style="margin-left:0cm; margin-right:1.95pt; text-align:right" dir="RTL">&bull; صعوبة في التنفس</p><p style="margin-left:0cm; margin-right:1.95pt; text-align:right" dir="RTL">&bull; انخفاض شديد في كمية البول</p><p style="margin-left:0cm; margin-right:2.05pt; text-align:right" dir="RTL">&bull; انخفاض مستوى الصوديوم في الدم (و يمكن أن يؤدي إلى التعب والارتباك، وارتعاش العضلات و / أو تشنجات في الحالات الشديدة)</p><p style="margin-left:0cm; margin-right:1.95pt; text-align:right" dir="RTL">&bull; انخفاض مستوى البوتاسيوم في الدم (في بعض الأحيان مع ضعف العضلات، وتشنجات العضلات، وضربات القلب غير طبيعية)</p><p style="margin-left:0cm; margin-right:1.75pt; text-align:right" dir="RTL">&bull; انخفاض مستوى الخلايا البيضاء في الدم (مع أعراض مثل الحمى، والتهابات الجلد، والتهاب الحلق أو قرح الفم بسبب الالتهابات، وضعف عام)</p><p style="margin-left:0cm; margin-right:1.95pt; text-align:right" dir="RTL">&bull; زيادة مستوى البيليروبين في الدم (والتي يمكن، في الحالات الشديدة، أن تؤدي إلى إصفرار البشرة والعيون)</p><p style="margin-left:0cm; margin-right:2.0pt; text-align:right" dir="RTL">&bull; زيادة مستوى نتروجين اليوريا في الدم والكرياتينين في الدم (والتي يمكن أن تشير إلى إعتلال وظيفة الكلى)</p><p style="margin-left:0cm; margin-right:2.0pt; text-align:right" dir="RTL">&bull; زيادة مستوى حمض اليوريك في الدم (التي يمكن، في الحاالت الشديدة، أن تؤدي إلى النقرس)</p><p style="margin-left:0cm; margin-right:1.9pt; text-align:right" dir="RTL">&bull; الإغماء</p><p>تم الإبلاغ عن الآثار الجانبية التالية مع المنتجات التي تحتوي على ڤالسارتان أو هيدروكلوروثيازيد وحدها.</p><p style="text-align:right" dir="RTL"><strong>ال<u>ڤالسارتان</u></strong></p><p style="text-align:right" dir="RTL"><strong>غير شائعة</strong><strong>:</strong></p><p style="margin-left:0cm; margin-right:1.95pt; text-align:right" dir="RTL">&bull; الإحساس بالدوار</p><p style="margin-left:0cm; margin-right:1.95pt; text-align:right" dir="RTL">&bull; ألم في البطن.</p><p>غير معروفة:</p><p style="margin-left:0cm; margin-right:2.0pt; text-align:right" dir="RTL">&bull; طفح جلدي مع أو بدون حكة جنبا إلى جنب مع بعض من العلامات أو الأعراض التالية: ارتفاع درجة الحرارة وآلام المفاصل، وآلام في</p><p style="text-align:right" dir="RTL">العضلات، وتضخم الغدد الليمفاوية و / أو أعراض تشبه الانفلونزا</p><p style="margin-left:0cm; margin-right:2.0pt; text-align:right" dir="RTL">&bull; طفح جلدي ،تبقع جلدي أرجواني &ndash; محمر، حمى ، والحكة (أعراض التهاب الأوعية الدموية)</p><p style="margin-left:0cm; margin-right:2.0pt; text-align:right" dir="RTL">&bull; انخفاض مستوى الصفائح الدموية (وأحيانا مع نزيف غير عادي أو كدمات)</p><p style="margin-left:0cm; margin-right:2.0pt; text-align:right" dir="RTL">&bull; مستوى عال من البوتاسيوم في الدم (في بعض الأحيان مع تشنجات العضلات، وضربات القلب غير طبيعية)</p><p style="margin-left:0cm; margin-right:1.95pt; text-align:right" dir="RTL">&bull; تفاعلات تحسسية (مع أعراض مثل الطفح الجلدي، والحكة، و الشري، وصعوبة في التنفس أوالبلع، والدوخة)</p><p style="margin-left:0cm; margin-right:1.95pt; text-align:right" dir="RTL">&bull; تورم بشكل أساسي في الوجه والحلق. الطفح الجلدي. الحكة</p><p style="margin-left:0cm; margin-right:1.95pt; text-align:right" dir="RTL">&bull; ارتفاع قيم وظائف الكبد</p><p style="margin-left:0cm; margin-right:1.95pt; text-align:right" dir="RTL">&bull; انخفاض مستوى الهيموغلوبين ونسبة خلايا الدم الحمراء في الدم (والتي يمكن، في الحالات الشديدة، أن تؤدي إلى فقر الدم.)</p><p style="margin-left:0cm; margin-right:1.95pt; text-align:right" dir="RTL">&bull; الفشل الكلوي.</p><p style="margin-left:0cm; margin-right:2.05pt; text-align:right" dir="RTL">&bull; انخفاض مستوى الصوديوم في الدم (والذي يمكن أن يؤدي إلى التعب والارتباك، وارتعاش العضلات و / أو تشنجات في الحالات الشديدة)</p><p style="text-align:right" dir="RTL"><strong>ه<u>يدروكلوروثيازيد</u></strong></p><p style="text-align:right" dir="RTL"><strong>شائعة جدا</strong><strong>:</strong></p><p style="margin-left:0cm; margin-right:1.95pt; text-align:right" dir="RTL">&bull; انخفاض مستوى البوتاسيوم في الدم</p><p style="margin-left:0cm; margin-right:1.95pt; text-align:right" dir="RTL">&bull; زيادة نسبة الدهون في الدم</p><p>&nbsp;</p><p>شائعة:</p><p style="margin-left:0cm; margin-right:1.95pt; text-align:right" dir="RTL">&bull; انخفاض مستوى الصوديوم في الدم</p><p style="margin-left:0cm; margin-right:1.95pt; text-align:right" dir="RTL">&bull; انخفاض مستوى المغنيسيوم في الدم</p><p style="margin-left:0cm; margin-right:1.95pt; text-align:right" dir="RTL">&bull; مستوى عال من حمض اليوريك في الدم</p><p style="margin-left:0cm; margin-right:1.95pt; text-align:right" dir="RTL">&bull; طفح جلدي وحكة وغيرها من أنواع الطفح الجلدي</p><p style="margin-left:0cm; margin-right:1.9pt; text-align:right" dir="RTL">&bull; انخفاض الشهية</p><p style="margin-left:0cm; margin-right:1.95pt; text-align:right" dir="RTL">&bull; غثيان وقيء معتدل</p><p style="margin-left:0cm; margin-right:1.9pt; text-align:right" dir="RTL">&bull; الدوخة، والإغماء عند الوقوف</p><p style="margin-left:0cm; margin-right:2.0pt; text-align:right" dir="RTL">&bull; عدم القدرة على تحقيق أو الحفاظ على الانتصاب</p><p>نادرة:</p><p style="margin-left:0cm; margin-right:2.0pt; text-align:right" dir="RTL">&bull; تورم وظهور تقرحات في الجلد (بسبب زيادة الحساسية لأشعة الشمس)</p><p style="margin-left:0cm; margin-right:1.95pt; text-align:right" dir="RTL">&bull; مستوى عال من الكالسيوم في الدم</p><p style="margin-left:0cm; margin-right:1.95pt; text-align:right" dir="RTL">&bull; مستوى عال من السكر في الدم</p><p style="margin-left:0cm; margin-right:1.95pt; text-align:right" dir="RTL">&bull; سكر في البول</p><p style="margin-left:0cm; margin-right:1.95pt; text-align:right" dir="RTL">&bull; تدهور الأيض لدى مرضى السكري</p><p style="margin-left:0cm; margin-right:2.0pt; text-align:right" dir="RTL">&bull; الإمساك، الإسهال، عدم الراحة في المعدة أو الأمعاء، اضطرابات الكبد التي يمكن أن تحدث مع إصفرار الجلد أو العينين.</p><p style="margin-left:0cm; margin-right:1.95pt; text-align:right" dir="RTL">&bull; عدم انتظام ضربات القلب</p><p style="margin-left:0cm; margin-right:1.9pt; text-align:right" dir="RTL">&bull; الصداع</p><p style="margin-left:0cm; margin-right:1.95pt; text-align:right" dir="RTL">&bull; اضطرابات النوم</p><p style="margin-left:0cm; margin-right:1.9pt; text-align:right" dir="RTL">&bull; مزاج حزين (الاكتئاب)</p><p style="margin-left:0cm; margin-right:1.95pt; text-align:right" dir="RTL">&bull; انخفاض مستوى الصفائح الدموية (وأحيانا مع نزيف أو كدمات تحت الجلد.)</p><p style="margin-left:0cm; margin-right:1.9pt; text-align:right" dir="RTL">&bull; الدوخة</p><p style="margin-left:0cm; margin-right:1.9pt; text-align:right" dir="RTL">&bull; وخز أو خدر</p><p style="margin-left:0cm; margin-right:1.95pt; text-align:right" dir="RTL">&bull; اضطراب الرؤية</p><p>نادرة جدا:</p><p style="margin-left:0cm; margin-right:2.05pt; text-align:right" dir="RTL">&bull; التهاب الأوعية الدموية مع أعراض مثل الطفح الجلدي تبقع جلدي أرجواني &ndash; محمر ، والحمى (التهاب الأوعية الدموية)</p><p style="margin-left:0cm; margin-right:1.9pt; text-align:right" dir="RTL">&bull; الطفح الجلدي، والحكة، و الشري، وصعوبة في التنفس أو البلع، والدوخة (تفاعالت فرط الحساسية)</p><p style="margin-left:0cm; margin-right:2.0pt; text-align:right" dir="RTL">&bull; (انحلال البشرة السمي) و هو مرض الجلد الشديد الذي يسبب الطفح الجلدي، احمرار الجلد، ظهور تقرحات الشفاه والعينين أو الفم،</p><p style="margin-left:0cm; margin-right:3.95pt; text-align:right" dir="RTL">تقشير الجلد، والحمى</p><p style="margin-left:0cm; margin-right:1.95pt; text-align:right" dir="RTL">&bull; طفح جلدي في الوجه، وآلآم المفاصل، واضطرابات العضلات والحمى (الذئبة الحمامية)</p><p style="margin-left:0cm; margin-right:1.95pt; text-align:right" dir="RTL">&bull; آلام حادة في أعلى المعدة (التهاب البنكرياس)</p><p style="margin-left:0cm; margin-right:2.05pt; text-align:right" dir="RTL">&bull; صعوبة في التنفس مع الحمى والسعال والصفير عند التنفس، انقطاع النفس (ضيق التنفس بما في ذلك التهاب رئوي و وذمة رئوية)</p><p style="margin-left:0cm; margin-right:1.95pt; text-align:right" dir="RTL">&bull; الحمى، والتهاب الحلق، التهابات متكررة (ندرة المحببات)</p><p style="margin-left:0cm; margin-right:1.95pt; text-align:right" dir="RTL">&bull; شحوب البشرة، والتعب و انقطاع النفس والبول الداكن (فقر الدم الانحلالي)</p><p style="margin-left:0cm; margin-right:1.95pt; text-align:right" dir="RTL">&bull; الحمى، والتهاب الحلق أو تقرحات الفم بسبب العدوى (نقص الكريات البيض)</p><p style="margin-left:0cm; margin-right:1.95pt; text-align:right" dir="RTL">&bull; الارتباك، والتعب، وارتعاش العضلات وتشنج، وسرعة التنفس</p><p>غير معروفة:</p><p style="margin-left:0cm; margin-right:1.9pt; text-align:right" dir="RTL">&bull; ضعف، وكدمات وإصابات متكررة (فقر الدم)</p><p style="margin-left:0cm; margin-right:2.0pt; text-align:right" dir="RTL">&bull; انخفاض شديد بكمية البول (علامات محتملة لاضطرابات وظائف الكلى أو الفشل الكلوي)</p><p style="margin-left:0cm; margin-right:1.95pt; text-align:right" dir="RTL">&bull; انخفاض في الرؤية أو ألم في عينيك بسبب الضغط العالي (علامات محتملة لحالة حادة من الماء الأزرق)</p><p style="margin-left:0cm; margin-right:1.9pt; text-align:right" dir="RTL">&bull; الطفح الجلدي، احمرار الجلد، ظهور تقرحات الشفاه والعينين أو الفم، تقشر الجلد، والحمى (علامات محتملة من &nbsp;&nbsp;ُحمامي متعدد الأشكال)</p><p style="margin-right:1.9pt; text-align:right" dir="RTL">&bull; تشنج العضلات</p><p style="margin-left:0cm; margin-right:1.9pt; text-align:right" dir="RTL">&bull; الحمى</p><p style="margin-left:0cm; margin-right:1.9pt; text-align:right" dir="RTL">&bull; ضعف (الوهن)</p><p style="text-align:right" dir="RTL">إذا كان أي من الآثار الجانبية جدية أو إذا لاحظت أي آثار جانبية غير المذكورة في هذه النشرة، يرجى إخبار الطبيب أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p style="margin-right:.05pt; text-align:right" dir="RTL">يحفظ بعيدا عن متناول الأطفال و نظرهم.</p><p style="margin-right:.05pt; text-align:right" dir="RTL">لا تستخدم أقراص<strong> ديوستار</strong><strong>- بلص</strong><strong>&reg;</strong>&nbsp;بعد تاريخ انتهاء الصلاحية المذكورعلى الشريط و العلبة الخارجية.</p><p style="margin-right:.05pt; text-align:right" dir="RTL">تاريخ الانتهاء يشير إلى اليوم الاخير من ذلك الشهر. <strong>ديوستار</strong><strong>- بلص</strong><strong>&reg;</strong>&nbsp; أقراص: يحفظ&nbsp; بدرجة حرارة دون 30 &deg;م</p><p style="margin-right:.05pt; text-align:right" dir="RTL">يجب أن لا يتم التخلص من الادوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الادوية التي لم تعد مطلوبة. وسوف تساعد هذه التدابير في حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>المواد الفعالة هي ڤالسارتان وهيدروكلوروثيازيد. المكونات الأخرى هي ميكروكريستالين سيليلوز، كروسكارميللوز صوديوم، بوفيدون K30، ثاني أكسيد السيليكون الغروي، ستيرات المغنيسيوم،، أوبادري أبيض، C &amp; FD الاحمر # 40، C &amp; FD الازرق # .1</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p style="margin-left:118.25pt; text-align:center; text-indent:114.25pt" dir="RTL">أقراص<strong> ديوستار</strong><strong>-</strong><strong> </strong><strong>بل</strong><strong>ص</strong><strong>&reg;</strong><strong>&nbsp;</strong><strong>160</strong><strong> </strong><strong>ملغم</strong><strong> </strong><strong>/</strong><strong> </strong><strong>12.5</strong><strong>ملغم</strong></p><p style="margin-left:118.25pt; text-align:center; text-indent:114.25pt" dir="RTL">أقراص مستطيلة الشكل منحنية على الأطراف، ذات لون أرجواني، محدبة الوجهين و مغلفة بفيلم. على أحد الوجهين يوجد خط للكسر و على الوجه الآخر محفور PhI . معبأة في أشرطة من المنيوم / الألمنيوم، ومعدة لالستخدام عن طريق الفم.</p><p style="text-align:center" dir="RTL">حجم العبوة: 30 قرصاً&nbsp;10( أقراص / شريط، 3 أشرطة / علبة)</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p style="margin-left:274.15pt; margin-right:0cm; text-align:right; text-indent:-7.75pt" dir="RTL">الدولية للدواء</p><p style="margin-left:274.15pt; margin-right:0cm; text-align:right; text-indent:-7.75pt" dir="RTL">عمان - األردن</p><p style="text-align:right">00962 - 6 - 5158890 / 5157893 :الهاتف</p><p style="text-align:right">00962 - 6 - 5154753 :فاكس</p><p style="text-align:right" dir="RTL">البريد اإللكتروني:&nbsp; marketing@pic-jo.com</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            10/2015
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Diostar- plus® 160/12.5 mg film-coated tablets. 
Valsartan Hydrochlorothiazide 160 mg/12.5 mg film-coated tablets 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Diostar- plus® 160/12.5 mg Tablets: Each tablet contains 160mg valsartan and 12.5mg hydrochlorothiazide.
For a full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Diostar-plus® tablets are film coated tablets.
Diostar-plus® 160 mg/12.5 mg are purple oblong deep biconvex film coated tablet, scored on one face & engraved with PhI on the other, packed in Alu/Alu blister, intended for oral use.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:left">Treatment of essential hypertension in adults.</p><p style="margin-right:49.3pt; text-align:left"><strong>Diostar-plus</strong><strong>&reg; </strong>fixed-dose combination is indicated in patients whose blood pressure is not adequately controlled on valsartan or hydrochlorothiazide monotherapy.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:left"><em>Posology</em></p><p style="text-align:left">The recommended dose of <strong>Diostar- plus</strong><strong>&reg; </strong>80/12.5mg or 160/12.5mg or 160/25mg is one film-coated tablet once daily. Dose titration with the individual components is recommended. In each case, up- titration of individual components to the next dose should be followed in order to reduce the risk of hypotension and other adverse events.</p><p style="margin-right:11.4pt; text-align:left">When clinically appropriate direct change from monotherapy to the fixed combination may be considered in patients whose blood pressure is not adequately controlled on valsartan or hydrochlorothiazide monotherapy, provided the recommended dose titration sequence for the individual components is followed.</p><p style="margin-right:20.8pt; text-align:left">The clinical response to <strong>Diostar- plus</strong><strong>&reg; </strong>should be evaluated after initiating therapy and if blood pressure remains uncontrolled, the dose may be increased by increasing either one of the components to a maximum dose of <strong>Diostar- plus</strong><strong>&reg; </strong>320 mg/25 mg.</p><p style="text-align:left">The antihypertensive effect is substantially present within 2 weeks.</p><p style="margin-right:22.75pt; text-align:left">In most patients, maximal effects are observed within 4 weeks. However, in some patients, 4-8 weeks treatment may be required. This should be taken into account during dose-titration.</p><p style="margin-right:22.75pt; text-align:left">&nbsp;</p><p style="margin-right:22.75pt; text-align:left"><em>Method of administration</em></p><p style="margin-right:22.75pt; text-align:left"><strong>Diostar- plus</strong><strong>&reg; </strong>can be taken with or without food and should be administered with water.</p><p style="margin-right:22.75pt; text-align:left"><em>Special populations Renal impairment</em></p><p style="margin-right:66.8pt; text-align:left">No dose adjustment is required for patients with mild to moderate renal impairment (Glomerular Filtration Rate (GFR) &ge; 30 ml/min). Due to the</p><p style="text-align:left">&nbsp;</p><p style="text-align:left">hydrochlorothiazide component, <strong>Diostar- plus</strong><strong>&reg; </strong>is contraindicated in patients with severe renal impairment (GFR &lt; 30 mL/min) and anuria (see sections 4.3,</p><p style="margin-right:36.45pt; text-align:left">4.4 and 5.2). Concomitant use of valsartan with aliskiren is contraindicated in patients with renal impairment (GFR &lt; 60 mL/min/1.73 m2) (see section 4.3). <em>Diabetes Mellitus</em></p><p style="margin-right:36.1pt; text-align:left">Concomitant use of valsartan with aliskiren is contraindicated in patients with diabetes mellitus (see section 4.3).</p><p style="margin-right:36.1pt; text-align:left">&nbsp;</p><p style="margin-right:36.1pt; text-align:left"><em>Hepatic impairment</em></p><p style="margin-right:36.1pt; text-align:left">&nbsp;</p><p style="margin-right:36.1pt; text-align:left">In patients with mild to moderate hepatic impairment without cholestasis the dose of valsartan should not exceed 80 mg (see section 4.4). No adjustment of the hydrochlorothiazide dose is required for patients with mild to moderate hepatic impairment. Due to the valsartan component, <strong>Diostar- plus</strong><strong>&reg;&nbsp; </strong>is contraindicated in patients with severe hepatic impairment or with biliary cirrhosis and cholestasis (see sections 4.3, 4.4 and 5.2).</p><p style="margin-right:36.1pt; text-align:left">&nbsp;</p><p style="margin-right:36.1pt; text-align:left"><em>Elderly</em></p><p style="text-align:left">No dose adjustment is required in elderly patients.</p><p style="text-align:left">&nbsp;</p><p style="text-align:left"><em>Paediatric patients</em></p><p style="text-align:left"><strong>Diostar- plus&reg; </strong>is not recommended for use in children below the age of 18 years due to a lack of data on safety and efficacy.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                
-	Hypersensitivity to valsartan, hydrochlorothiazide, other sulfonamide-derived medicinal products or to any of the excipients.
-	Second and third trimester of pregnancy (section 4.4 and 4.6).
-	Severe hepatic impairment, biliary cirrhosis and cholestasis.
-	Severe renal impairment (creatinine clearance < 30 ml/min), anuria.
-	Refractory hypokalaemia, hyponatraemia, hypercalcaemia, and symptomatic hyperuricaemia.
-	Concomitant use of angiotensin receptor antagonists (ARBs) – including valsartan – or of angiotensin-converting-enzyme inhibitors (ACEIs) with aliskiren in patients with diabetes mellitus or renal impairment (GFR < 60 mL/min/1.73m2) (see sections 4.4 and 4.5).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:left">Serum electrolyte changes</p><p style="margin-left:34pt; text-align:left"><em>Valsartan</em></p><p style="margin-left:34pt; text-align:left">Concomitant use with potassium supplements, potassium-sparing diuretics, salt substitutes containing potassium, or other agents that may increase potassium levels (heparin, etc.) is not recommended. Monitoring of potassium should be undertaken as appropriate.</p><p style="margin-left:34pt; text-align:left"><em>Hydrochlorothiazide</em></p><p style="margin-left:34pt; margin-right:54.1pt; text-align:left">Hypokalaemia has been reported under treatment with thiazide diuretics, including hydrochlorothiazide. Frequent monitoring of serum potassium is recommended.</p><p style="margin-right:56.75pt; text-align:left">Treatment with thiazide diuretics, including hydrochlorothiazide has been associated with hyponatraemia and hypochloraemic alkalosis. Thiazides,</p><p style="text-align:left">&nbsp;</p><p style="text-align:left">including hydrochlorothiazide increase the urinary excretion of magnesium, which may result in hypomagnesaemia. Calcium excretion is decreased by thiazide diuretics. This may result in hypercalcaemia.</p><p style="text-align:left">As for any patient receiving diuretic therapy, periodic determination of serum electrolytes should be performed at appropriate intervals.</p><p style="text-align:left">Sodium, and/or volume-depleted patients</p><p style="margin-right:35.4pt; text-align:left">Patients receiving thiazide diuretics, including hydrochlorothiazide, should be observed for clinical signs of fluid or electrolyte imbalance.</p><p style="margin-right:20.8pt; text-align:left">In severely sodium-depleted and/or volume-depleted patients, such as those receiving high doses of diuretics, symptomatic hypotension may occur in rare cases after initiation of therapy with <strong>Diostar- plus</strong><strong>&reg;</strong>. Sodium and/or volume depletion should be corrected before starting treatment with <strong>Diostar- plus</strong><strong>&reg;</strong>. Patients with severe chronic heart failure or other conditions with stimulation of the renin-angiotensin-aldosterone-system</p><p style="text-align:left">In patients whose renal function may depend on the activity of the</p><p style="margin-right:11.4pt; text-align:left">renin-angiotensin-aldosterone system (e.g. patients with severe congestive heart failure), treatment with angiotensin converting enzyme inhibitors has been associated with oliguria and/or progressive azotaemia, and in rare cases with acute renal failure and/or death. Evaluation of patients with heart failure or</p><p style="margin-right:26.7pt; text-align:left">post-myocardial infarction should always include assessment of renal function. The use of <strong>Diostar- plus</strong><strong>&reg; </strong>in patients with severe chronic heart failure has not been established.</p><p style="text-align:left">Hence it cannot be excluded that because of the inhibition of the</p><p style="margin-right:20.8pt; text-align:left">renin-angiotensin-aldosterone system the application of <strong>Diostar- plus</strong><strong>&reg; </strong>as well may be associated with impairment of the renal function. <strong>Diostar- plus</strong><strong>&reg; </strong>should not be used in these patients.</p><p style="text-align:left">Renal artery stenosis</p><p style="margin-right:20.8pt; text-align:left"><strong>Diostar- plus</strong><strong>&reg; </strong>should not be used to treat hypertension in patients with unilateral or bilateral renal artery stenosis or stenosis of the artery to a solitary kidney, since blood urea and serum creatinine may increase in such patients. Primary hyperaldosteronism</p><p style="margin-left:34pt; margin-right:34.1pt; text-align:left">Patients with primary hyperaldosteronism should not be treated with <strong>Diostar- plus</strong><strong>&reg; </strong>as their renin-angiotensin system is not activated.</p><p style="text-align:left">Aortic and mitral valve stenosis, hypertrophic obstructive cardiomyopathy</p><p style="margin-right:34.1pt; text-align:left">As with all other vasodilators, special caution is indicated in patients suffering from aortic or mitral stenosis, or hypertrophic obstructive cardiomyopathy (HOCM).</p><p style="text-align:left">Renal impairment</p><p style="margin-right:11.4pt; text-align:left">No dosage adjustment is required for patients with renal impairment with a creatinine clearance &gt; 30 ml/min (see section 4.2). Periodic monitoring of serum potassium, creatinine and uric acid levels is recommended when <strong>Diostar- plus</strong><strong>&reg; </strong>is used in patients with renal impairment.</p><p style="margin-right:12.75pt; text-align:left">The concomitant use of ARBs &ndash; including valsartan &ndash; or of ACEIs with aliskiren is contraindicated in patients with renal impairment (GFR &lt; 60 mL/min/1.73m2) (see sections 4.3 and 4.5).</p><p style="text-align:left">Kidney transplantation</p><p style="text-align:left">&nbsp;</p><p style="margin-left:34pt; margin-right:20.8pt; text-align:left">There is currently no experience on the safe use of <strong>Diostar- plus</strong><strong>&reg; </strong>in patients who have recently undergone kidney transplantation.</p><p style="text-align:left">Hepatic impairment</p><p style="margin-right:21.85pt; text-align:left">In patients with mild to moderate hepatic impairment without cholestasis<em>, </em><strong>Diostar- &nbsp;plus</strong><strong>&reg;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>should be used with caution (see sections 4.2 and 5.2)<em>. </em>Thiazides should be used with caution in patients with impaired hepatic function or progressive liver disease, since minor alterations of fluid and electrolyte balance may precipitate hepatic coma.</p><p style="text-align:left">History of angioedema</p><p style="margin-right:11.4pt; text-align:left">Angioedema, including swelling of the larynx and glottis, causing airway obstruction and/or swelling of the face, lips, pharynx, and/or tongue has been reported in patients treated with valsartan; some of these patients previously experienced angioedema with other drugs including ACE inhibitors. <strong>Diostar- plus</strong><strong>&reg; </strong>should be immediately discontinued in patients who develop angioedema, and <strong>Diostar- plus</strong><strong>&reg; </strong>should not be re-administered (see section 4.8).</p><p style="text-align:left">Systemic lupus erythematosus</p><p style="margin-right:64.1pt; text-align:left">Thiazide diuretics, including hydrochlorothiazide, have been reported to exacerbate or activate systemic lupus erythematosus.</p><p style="text-align:left">Other metabolic disturbances</p><p style="margin-right:11.4pt; text-align:left">Thiazide diuretics, including hydrochlorothiazide, may alter glucose tolerance and raise serum levels of cholesterol, triglycerides and uric acid. In diabetic patients dosage adjustments of insulin or oral hypoglycaemic agents may be required.</p><p style="margin-right:27.85pt; text-align:left">Thiazides may reduce urinary calcium excretion and cause an intermittent and slight elevation of serum calcium in the absence of known disorders of calcium metabolism.</p><p style="margin-left:34pt; margin-right:20.8pt; text-align:left">Marked hypercalcaemia may be evidence of underlying hyperparathyroidism. Thiazides should be discontinued before carrying out tests for parathyroid function.</p><p style="text-align:left">Photosensitivity</p><p style="margin-right:18.1pt; text-align:left">Cases of photosensitivity reactions have been reported with thiazides diuretics (see section 4.8). If photosensitivity reaction occurs during treatment, it is recommended to stop the treatment. If a re-administration of the diuretic is deemed necessary, it is recommended to protect exposed areas to the sun or to artificial UVA.</p><p style="text-align:left">Pregnancy</p><p style="margin-right:20.75pt; text-align:left">Angiotensin II Receptor Antagonists (AIIRAs) should not be initiated during pregnancy. Unless continued AIIRAs therapy is considered essential, patients planning pregnancy should be changed to alternative anti-hypertensive treatments which have an established safety profile for use in pregnancy. When pregnancy is diagnosed, treatment with AIIRAs should be stopped immediately, and, if appropriate, alternative therapy should be started (see sections 4.3 and 4.6).</p><p style="text-align:left">General</p><p style="text-align:left">Caution should be exercised in patients who have shown prior hypersensitivity to other angiotensin II receptor antagonists. Hypersensitivity reactions to hydrochlorothiazide are more likely in patients with allergy and asthma.</p><p style="text-align:left">&nbsp;</p><p style="text-align:left">Acute Angle-Closure Glaucoma</p><p style="margin-right:24.75pt; text-align:left">Hydrochlorothiazide, a sulfonamide, has been associated with an idiosyncratic reaction resulting in acute transient myopia and acute angle-closure glaucoma. Symptoms include acute onset of decreased visual acuity or ocular pain and typically occur within hours to week of a drug initiation. Untreated acute-angle closure glaucoma can lead to permanent vision loss.</p><p style="margin-right:13.4pt; text-align:left">The primary treatment is to discontinue hydrochlorothiazide as rapidly as possible. Prompt medical or surgical treatment may need to be considered if the intraocular pressure remains uncontrolled. Risk factors for developing acute angle closure glaucoma may include a history of sulfonamide or penicillin allergy. Dual Blockade of the Renin-Angiotensin-Aldosterone System (RAAS) Hypotension, syncope, stroke, hyperkalaemia, and changes in renal function (including acute renal failure) have been reported in susceptible individuals, especially if combining medicinal products that affect this system. Dual blockade of the renin-angiotensin-aldosterone system by combining aliskiren with an angiotensin converting enzyme inhibitor (ACEI) or an angiotensin II receptor blocker (ARB) is therefore not recommended.</p><p style="margin-left:34pt; margin-right:27.8pt; text-align:left">The use of aliskiren in combination with <strong>Diostar- plus</strong><strong>&reg; </strong>is contraindicated in patients with diabetes mellitus or renal impairment (GFR &lt; 60 ml/min/1.73 m2) (see section 4.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:left">Interactions related to both valsartan and hydrochlorothiazide</p><p style="margin-left:40px; margin-right:216.2pt; text-align:left"><em>Concomitant use not recommended Lithium</em></p><p style="margin-left:40px; margin-right:40.1pt; text-align:left">Reversible increases in serum lithium concentrations and toxicity have been reported during concurrent use of ACE inhibitors and thiazide, including hydrochlorothiazide. Due to the lack of experience with concomitant use of valsartan and lithium, this</p><p style="margin-right:24.75pt; text-align:left">combination is not recommended. If the combination proves necessary, careful monitoring of serum lithium levels is recommended.</p><p style="margin-left:40px; margin-right:260.85pt; text-align:left"><em>Concomitant use requiring caution Other antihypertensive agents</em></p><p style="text-align:left"><strong>Diostar- plus</strong><strong>&reg; </strong>may increase the effects of other agents with antihypertensive properties (e.g. guanethidine, methyldopa, vasodilators, ACEI, ARBs,</p><p style="text-align:left">beta-blockers, calcium channel blockers and DRIs).</p><p style="margin-left:40px; text-align:left"><em>Pressor amines </em>(e.g. noradrenaline, adrenaline)</p><p style="margin-left:40px; margin-right:18.75pt; text-align:left">Possible decreased response to pressor amines. The clinical significance of this effect is uncertain and not sufficient to preclude their use.</p><p style="margin-left:40px; margin-right:20.85pt; text-align:left"><em>Non-steroidal anti-inflammatory medicines (NSAIDs), including selective COX-2 inhibitors, acetylsalicylic acid (&gt;3 g/day), and non-selective NSAIDs</em></p><p style="margin-right:26.75pt; text-align:left">NSAIDS can attenuate the antihypertensive effect of both angiotensin II antagonists and hydrochlorothiazide when administered simultaneously. Furthermore, concomitant use of <strong>Diostar- plus</strong><strong>&reg; </strong>and NSAIDs may lead to worsening of renal function and an increase in serum potassium. Therefore, monitoring of renal function at the beginning of the treatment is recommended, as well as adequate hydration of the patient.</p><p style="text-align:left">&nbsp;</p><p style="text-align:left">Interactions related to valsartan</p><p style="margin-left:40px; margin-right:35.45pt; text-align:left"><em>Dual blockade of the Renin-Angiotensin-System (RAS) with ARBs, ACEIs, or aliskiren</em></p><p style="margin-left:40px; margin-right:21.45pt; text-align:left">Caution is required while co-administering ARBs, including valsartan, with other agents blocking the RAAS such as ACEIs or aliskiren (see section 4.4).</p><p style="margin-right:16.7pt; text-align:left">Concomitant use of angiotensin receptor antagonists (ARBs) &ndash; including valsartan &ndash; or of angiotensin-converting-enzyme inhibitors (ACEIs) with aliskiren in patients with diabetes mellitus or renal impairment (GFR &lt; 60 mL/min/1.73m2) is contraindicated (see section 4.3).</p><p style="margin-left:40px; text-align:left"><em>Concomitant use not recommended</em></p><p style="margin-left:40px; margin-right:18.75pt; text-align:left"><em>Potassium-sparing diuretics, potassium supplements, salt substitutes containing potassium and other substances that may increase potassium levels</em></p><p style="margin-left:40px; margin-right:31.3pt; text-align:left">If a medicinal product that affects potassium levels is considered necessary in combination with valsartan, monitoring of potassium plasma levels is advised. <em>Transporters</em></p><p style="margin-right:15.4pt; text-align:left">In vitro data indicates that valsartan is a substrate of the hepatic uptake transporter OATP1B1/OATP1B3 and the hepatic efflux transporter MRP2. The clinical relevance of this finding is unknown. Co-administration of inhibitors of the uptake transporter (eg. rifampin, ciclosporin) or efflux transporter (eg. ritonavir) may increase the systemic exposure to valsartan. Exercise appropriate care when initiating or ending concomitant treatment with such drugs.</p><p style="margin-left:40px; text-align:left"><em>No interaction</em></p><p style="margin-left:40px; margin-right:25.4pt; text-align:left">In drug interaction studies with valsartan, no interactions of clinical significance have been found with valsartan or any of the following substances: cimetidine, warfarin, furosemide, digoxin, atenolol, indomethacin, hydrochlorothiazide, amlodipine, glibenclamide. Digoxin and indomethacin could interact with the hydrochlorothiazide component of <strong>Diostar- plus</strong><strong>&reg; </strong>(see interactions related to hydrochlorothiazide).</p><p style="text-align:left">Interactions related to hydrochlorothiazide</p><p style="margin-left:40px; text-align:left"><em>Concomitant use requiring caution</em></p><p style="margin-left:40px; text-align:left"><em>Medicinal products affecting serum potassium level</em></p><p style="margin-left:40px; margin-right:20.8pt; text-align:left">The hypokalaemic effect of hydrochlorothiazide may be increased by concomitant administration of kaliuretic diuretics, corticosteroids, laxatives, ACTH, amphotericin, carbenoxolone, penicillin G, salicylic acid and derivatives.</p><p style="margin-right:41.15pt; text-align:left">If these medicinal products are to be prescribed with the hydrochlorothiazide-valsartan combination, monitoring of potassium plasma levels is advised (see section 4.4).</p><p style="margin-left:40px; text-align:left"><em>Medicinal products that could induce torsades de pointes</em></p><p style="margin-left:40px; margin-right:12.05pt; text-align:left">Due to the risk of hypokalaemia, hydrochlorothiazide should be administered with caution when associated with medicinal products that could induce torsades de pointes, in particular Class Ia and Class III antiarrhythmics and some antipsychotics.</p><p style="margin-left:40px; text-align:left"><em>Medicinal products affecting serum sodium level</em></p><p style="margin-left:40px; margin-right:27.4pt; text-align:left">The hyponatraemic effect of diuretics may be intensified by concomitant administration of drugs such as antidepressants, antipsychotics, antiepileptics, etc. Caution is advised in long-term administration of these drugs.</p><p style="text-align:left">&nbsp;</p><p style="margin-left:40px; margin-right:0cm; text-align:left"><em>Digitalis glycosides</em></p><p style="margin-left:40px; margin-right:11.4pt; text-align:left">Thiazide-induced hypokalaemia or hypomagnesaemia may occur as undesirable effects favouring the onset of digitalis-induced cardiac arrhythmias (see section 4.4).</p><p style="margin-left:40px; text-align:left"><em>Calcium salts and vitamin D</em></p><p style="margin-left:40px; margin-right:16.75pt; text-align:left">Administration of thiazide diuretics, including hydrochlorothiazide, with vitamin D or with calcium salts may potentiate the rise in serum calcium. Concomitant use of thiazide type diuretics with calcium salts may cause hypercalcaemia in patients pre-disposed for hypercalcaemia (e.g. hyperparathyroidism, malignancy or vitamin-D-mediated conditions) by increasing tubular calcium reabsorption.</p><p style="margin-left:40px; text-align:left"><em>Antidiabetic agents </em>(oral agents and insulin)</p><p style="margin-left:40px; margin-right:47.45pt; text-align:left">Thiazides may alter glucose tolerance. Dose adjustment of the antidiabetic medicinal product may be necessary.</p><p style="margin-right:43.45pt; text-align:left">Metformin should be used with caution because of the risk of lactic acidosis induced by possible functional renal failure linked to hydrochlorothiazide.</p><p style="margin-left:40px; text-align:left"><em>Beta blockers and diazoxide</em></p><p style="margin-left:40px; margin-right:26.8pt; text-align:left">Concomitant use of thiazide diuretics, including hydrochlorothiazide, with beta blockers may increase the risk of hyperglycaemia. Thiazide diuretics, including hydrochlorothiazide, may enhance the hyperglycaemic effect of diazoxide.</p><p style="margin-left:40px; margin-right:12.7pt; text-align:left"><em>Medicinal products used in the treatment of gout </em>(probenecid, sulfinpyrazone and allopurinol)</p><p style="text-align:left">Dose adjustment of uricosuric medications may be necessary as hydrochlorothiazide may raise the level of serum uric acid. Increase of dosage of probenecid or sulfinpyrazone may be necessary. Co-administration of thiazide diuretics, including hydrochlorothiazide, may increase the incidence of hypersensitivity reactions to allopurinol.</p><p style="margin-left:40px; text-align:left"><em>Anticholinergic agents and other medicinal products affecting gastric motility</em></p><p style="margin-right:14.05pt; text-align:left">The bioavailability of thiazide-type diuretics may be increased by anticholinergic agents (e.g. atropine, biperiden), apparently due to a decrease in gastrointestinal motility and the stomach emptying rate. Conversely, it is anticipated that prokinetic drugs such as cisapride may decrease the bioavailability of</p><p style="text-align:left">thiazide-type diuretics.</p><p style="margin-left:40px; text-align:left"><em>Amantadine</em></p><p style="margin-right:12.1pt; text-align:left">Thiazides, including hydrochlorothiazide, may increase the risk of adverse effects caused by amantadine.</p><p style="margin-left:40px; text-align:left"><em>Ion exchange resins</em></p><p style="margin-left:40px; margin-right:27.4pt; text-align:left">Absorption of thiazide diuretics, including hydrochlorothiazide, is decreased by cholestyramine or colestipol. This could result in sub-therapeutic effects of thiazide diuretics. However, staggering the dosage of hydrochlorothiazide and resin such that hydrochlorothiazide is administered at least 4 h before or 4-6 h after the administration of resins would potentially minimize the interaction.</p><p style="margin-left:40px; text-align:left"><em>Cytotoxic agents</em></p><p style="margin-left:40px; margin-right:11.4pt; text-align:left">Thiazides, including hydrochlorothiazide, may reduce renal excretion of cytotoxic agents (e.g. cyclophosamide, methotrexate) and potentiate their myelosuppressive effects.</p><p style="margin-left:40px; text-align:left"><em>Non-depolarising skeletal muscle relaxants </em>(e.g. tubocurarine)</p><p style="text-align:left">&nbsp;</p><p style="margin-left:40px; margin-right:16.75pt; text-align:left">Thiazides, including hydrochlorothiazide, potentiate the action of skeletal muscle relaxants such as curare derivatives.</p><p style="margin-left:40px; text-align:left"><em>Ciclosporin</em></p><p style="margin-left:40px; margin-right:21.45pt; text-align:left">Concomitant treatment with ciclosporin may increase the risk of hyperuricaemia and gout-type complications.</p><p style="margin-left:40px; text-align:left"><em>Alcohol, barbiturates or narcotics</em></p><p style="margin-left:40px; margin-right:11.4pt; text-align:left">Concomitant administration of thiazide diuretics with substances that also have a blood pressure lowering effect (e.g. by reducing sympathetic central nervous system activity or direct vasodilatation activity) may potentiate orthostatic hypotension.</p><p style="margin-left:40px; text-align:left"><em>Methyldopa</em></p><p style="text-align:left">There have been isolated reports of haemolytic anaemia in patients receiving concomitant treatment with methyldopa and hydrochlorothiazide.</p><p style="margin-left:40px; text-align:left"><em>Iodine contrast media</em></p><p style="margin-left:40px; margin-right:20.75pt; text-align:left">In case of diuretic-induced dehydration, there is an increased risk of acute renal failure, especially with high doses of the iodine product. Patients should be rehydrated before the administration.</p><p style="margin-left:0cm">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:left"><em>Pregnancy</em></p><p style="text-align:left">Valsartan</p><p style="margin-right:20.8pt; text-align:left">The use of Angiotensin II Receptor Antagonists (AIIRAs) is not recommended during first trimester of pregnancy (see section 4.4). The use of AIIRAs is</p><p style="margin-right:12.05pt; text-align:left">contra-indicated during the second and third trimester of pregnancy (see sections 4.3 and 4.4).</p><p style="text-align:left">&nbsp;</p><p style="margin-right:11.75pt; text-align:left">Epidemiological evidence regarding the risk of teratogenicity following exposure to ACE inhibitors during the first trimester of pregnancy has not been conclusive; however a small increase in risk cannot be excluded. Whilst there is no controlled epidemiological data on the risk with Angiotensin II Receptor Inhibitors (AIIRAs), similar risks may exist for this class of drugs. Unless continued AIIRAs therapy is considered essential, patients planning pregnancy should be changed to alternative anti-hypertensive treatments which have an established safety profile for use in pregnancy. When pregnancy is diagnosed, treatment with AIIRAs should be stopped immediately and, if appropriate, alternative therapy should be started.</p><p style="margin-right:42.4pt; text-align:left">AIIRAs therapy exposure during the second and third trimesters is known to induce human fetotoxicity (decreased renal function, oligohydramnios, skull ossification</p><p style="text-align:left">retardation) and neonatal toxicity (renal failure, hypotension, hyperkalaemia) (see also section 5.3).</p><p style="margin-right:20.8pt; text-align:left">Should exposure to AIIRAs have occurred from the second trimester of pregnancy, ultrasound check of renal function and skull is recommended. Infants whose mothers have taken AIIRAs should be closely observed for hypotension (see also section 4.3 and 4.4).</p><p style="text-align:left">&nbsp;</p><p style="text-align:left">Hydrochlorothiazide</p><p style="margin-right:12.1pt; text-align:left">There is limited experience with hydrochlorothiazide during pregnancy, especially during the first trimester. Animal studies are insufficient. Hydrochlorothiazide crosses the placenta. Based on the pharmacological mechanism of action of hydrochlorothiazide its use during the second and third trimester may compromise foeto-placental perfusion and may cause foetal and neonatal effects like icterus, disturbance of electrolyte balance and thrombocytopenia.</p><p style="text-align:left"><em>Lactation</em></p><p style="margin-right:16.75pt; text-align:left">No information is available regarding the use of valsartan during breastfeeding. Hydrochlorothiazide is excreted in human milk. Therefore the use of <strong>Diostar- plus</strong><strong>&reg; </strong>during breast feeding is not recommended. Alternative treatments with better established safety profiles during breast-feeding are preferable, especially while nursing a newborn or preterm infant.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:left">No studies on the effect of <strong>Diostar- plus</strong><strong>&reg;</strong>, on the ability to drive and use machines have been performed. When driving vehicles or operating machines it should be taken into account that occasionally dizziness or weariness may occur.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-right:14.4pt; text-align:left">Adverse reactions reported in clinical trials and laboratory findings occurring more frequently with valsartan plus hydrochlorothiazide versus placebo and individual post-marketing reports are presented below according to system organ class. Adverse reactions known to occur with each component given individually but which have not been seen in clinical trials may occur during treatment with valsartan/ hydrochlorothiazide.</p><p style="margin-right:15.4pt; text-align:left">Adverse drug reactions are ranked by frequency, the most frequent first, using the following convention: very common (&ge; 1/10); common (&ge; 1/100 to &lt; 1/10); uncommon (&ge; 1/1,000 to &lt; 1/100); rare(&ge; 1/10,000 to <em>&lt; </em>1/1,000); very rare (&lt; 1/10,000), not known (cannot be estimated from the available data). Within each frequency grouping, adverse reactions are ranked in order of decreasing seriousness.</p><p style="text-align:left">Table 1. Frequency of adverse reactions with valsartan/hydrochlorothiazide</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="height:13.6pt; vertical-align:top; width:220.65pt" colspan="2"><p style="text-align:left"><strong>Metabolism and nutrition disorders</strong></p></td></tr><tr><td style="height:13.8pt; vertical-align:top; width:90.55pt"><p style="text-align:left">Uncommon</p></td><td style="height:13.8pt; vertical-align:top; width:130.1pt"><p style="margin-left:19.15pt; text-align:left">Dehydration</p></td></tr><tr><td style="height:13.8pt; vertical-align:top; width:220.65pt" colspan="2"><p style="text-align:left"><strong>Nervous system disorders</strong></p></td></tr><tr><td style="height:13.8pt; vertical-align:top; width:90.55pt"><p style="text-align:left">Very rare</p></td><td style="height:13.8pt; vertical-align:top; width:130.1pt"><p style="margin-left:19.15pt; text-align:left">Dizziness</p></td></tr><tr><td style="height:13.75pt; vertical-align:top; width:90.55pt"><p style="text-align:left">Uncommon</p></td><td style="height:13.75pt; vertical-align:top; width:130.1pt"><p style="margin-left:19.15pt; text-align:left">Paraesthesia</p></td></tr><tr><td style="height:13.8pt; vertical-align:top; width:90.55pt"><p style="text-align:left">Not known</p></td><td style="height:13.8pt; vertical-align:top; width:130.1pt"><p style="margin-left:19.15pt; text-align:left">Syncope</p></td></tr><tr><td style="height:13.6pt; vertical-align:top; width:90.55pt"><p style="text-align:left"><strong>Eye disorders</strong></p></td><td style="height:13.6pt; vertical-align:top; width:130.1pt"><p style="margin-left:0cm; text-align:left">&nbsp;</p></td></tr></tbody></table><p style="margin-left:0cm; margin-right:0cm; text-align:left">&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="height:13.6pt; vertical-align:top; width:92.45pt"><p style="text-align:left">Uncommon</p></td><td style="height:13.6pt; vertical-align:top; width:104.45pt"><p style="margin-left:21.1pt; text-align:left">Vision blurred</p></td></tr><tr><td style="height:41.35pt; vertical-align:top; width:92.45pt"><p style="margin-right:26.75pt; text-align:left"><strong>Ear and labyrinth disorders</strong></p></td><td style="height:41.35pt; vertical-align:top; width:104.45pt"><p style="margin-left:0cm; text-align:left">&nbsp;</p></td></tr><tr><td style="height:13.6pt; vertical-align:top; width:92.45pt"><p style="text-align:left">Uncommon</p></td><td style="height:13.6pt; vertical-align:top; width:104.45pt"><p style="margin-left:21.1pt; text-align:left">Tinnitus</p></td></tr></tbody></table><p style="text-align:left">&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="height:13.6pt; vertical-align:top; width:410.85pt" colspan="2"><p style="text-align:left"><strong>Vascular disorders</strong></p></td></tr><tr><td style="height:13.75pt; vertical-align:top; width:92.45pt"><p style="text-align:left">Uncommon</p></td><td style="height:13.75pt; vertical-align:top; width:318.4pt"><p style="margin-left:21.1pt; text-align:left">Hypotension</p></td></tr><tr><td style="height:13.75pt; vertical-align:top; width:410.85pt" colspan="2"><p style="text-align:left"><strong>Respiratory, thoracic and mediastinal disorders</strong></p></td></tr><tr><td style="height:13.8pt; vertical-align:top; width:92.45pt"><p style="text-align:left">Uncommon</p></td><td style="height:13.8pt; vertical-align:top; width:318.4pt"><p style="margin-left:21.1pt; text-align:left">Cough</p></td></tr><tr><td style="height:13.75pt; vertical-align:top; width:92.45pt"><p style="text-align:left">Not known</p></td><td style="height:13.75pt; vertical-align:top; width:318.4pt"><p style="margin-left:21.1pt; text-align:left">Non cardiogenic pulmonary oedema</p></td></tr><tr><td style="height:13.8pt; vertical-align:top; width:410.85pt" colspan="2"><p style="text-align:left"><strong>Gastrointestinal disorders</strong></p></td></tr><tr><td style="height:13.75pt; vertical-align:top; width:92.45pt"><p style="text-align:left">Very rare</p></td><td style="height:13.75pt; vertical-align:top; width:318.4pt"><p style="margin-left:21.1pt; text-align:left">Diarrhoea</p></td></tr><tr><td style="height:13.75pt; vertical-align:top; width:410.85pt" colspan="2"><p style="text-align:left"><strong>Musculoskeletal and connective tissue disorders</strong></p></td></tr><tr><td style="height:13.8pt; vertical-align:top; width:92.45pt"><p style="text-align:left">Uncommon</p></td><td style="height:13.8pt; vertical-align:top; width:318.4pt"><p style="margin-left:21.1pt; text-align:left">Myalgia</p></td></tr><tr><td style="height:13.75pt; vertical-align:top; width:92.45pt"><p style="text-align:left">Very rare</p></td><td style="height:13.75pt; vertical-align:top; width:318.4pt"><p style="margin-left:21.1pt; text-align:left">Arthralgia</p></td></tr><tr><td style="height:13.8pt; vertical-align:top; width:410.85pt" colspan="2"><p style="text-align:left"><strong>Renal and urinary disorders</strong></p></td></tr><tr><td style="height:13.8pt; vertical-align:top; width:92.45pt"><p style="text-align:left">Not known</p></td><td style="height:13.8pt; vertical-align:top; width:318.4pt"><p style="margin-left:21.1pt; text-align:left">Impaired renal function</p></td></tr><tr><td style="height:13.8pt; vertical-align:top; width:410.85pt" colspan="2"><p style="text-align:left"><strong>General disorders and administration site conditions</strong></p></td></tr><tr><td style="height:13.75pt; vertical-align:top; width:92.45pt"><p style="text-align:left">Uncommon</p></td><td style="height:13.75pt; vertical-align:top; width:318.4pt"><p style="margin-left:21.1pt; text-align:left">Fatigue</p></td></tr><tr><td style="height:13.75pt; vertical-align:top; width:92.45pt"><p style="text-align:left"><strong>Investigations</strong></p></td><td style="height:13.75pt; vertical-align:top; width:318.4pt"><p style="margin-left:0cm; text-align:left">&nbsp;</p></td></tr><tr><td style="height:41.2pt; vertical-align:top; width:92.45pt"><p style="text-align:left">Not known</p></td><td style="height:41.2pt; vertical-align:top; width:318.4pt"><p style="margin-left:21.1pt; text-align:left">Serum uric acid increased, Serum bilirubin and Serum creatinine increased, Hypokalaemia, Hyponatraemia, Elevation of Blood Urea Nitrogen, Neutropenia</p></td></tr></tbody></table><p style="margin-left:0cm; margin-right:0cm; text-align:left">&nbsp;</p><p style="text-align:left">Additional information on the individual components</p><p style="margin-right:13pt; text-align:left">Adverse reactions previously reported with one of the individual components may be potential undesirable effects with <strong>Diostar-&nbsp; plus</strong><strong>&reg;&nbsp; </strong>as well, even if not observed in clinical trials or during postmarketing period.</p><p style="text-align:left">Table 2. Frequency of adverse reactions with valsartan</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="height:13.6pt; vertical-align:top; width:437.6pt" colspan="2"><p style="text-align:left"><strong>Blood and lymphatic system disorders</strong></p></td></tr><tr><td style="height:27.55pt; vertical-align:top; width:76.8pt"><p style="text-align:left">Not known</p></td><td style="height:27.55pt; vertical-align:top; width:360.8pt"><p style="margin-left:5.4pt; margin-right:80.2pt; text-align:left">Decrease in haemoglobin, decrease in haematocrit, thrombocytopenia</p></td></tr><tr><td style="height:13.8pt; vertical-align:top; width:437.6pt" colspan="2"><p style="text-align:left"><strong>Immune system disorders</strong></p></td></tr><tr><td style="height:19.35pt; vertical-align:top; width:76.8pt"><p style="text-align:left">Not known</p></td><td style="height:19.35pt; vertical-align:top; width:360.8pt"><p style="margin-left:5.4pt; text-align:left">Other hypersensitivity/allergic reactions including serum sickness</p></td></tr><tr><td style="height:19.35pt; vertical-align:top; width:437.6pt" colspan="2"><p style="text-align:left"><strong>Metabolism and nutrition disorders</strong></p></td></tr><tr><td style="height:13.75pt; vertical-align:top; width:76.8pt"><p style="text-align:left">Not known</p></td><td style="height:13.75pt; vertical-align:top; width:360.8pt"><p style="margin-left:5.4pt; text-align:left">Increase of serum potassium, hyponatraemia</p></td></tr><tr><td style="height:13.8pt; vertical-align:top; width:437.6pt" colspan="2"><p style="text-align:left"><strong>Ear and labyrinth disorders</strong></p></td></tr><tr><td style="height:13.75pt; vertical-align:top; width:76.8pt"><p style="text-align:left">Uncommon</p></td><td style="height:13.75pt; vertical-align:top; width:360.8pt"><p style="margin-left:5.4pt; text-align:left">Vertigo</p></td></tr><tr><td style="height:13.8pt; vertical-align:top; width:437.6pt" colspan="2"><p style="text-align:left"><strong>Vascular disorders</strong></p></td></tr><tr><td style="height:13.8pt; vertical-align:top; width:76.8pt"><p style="text-align:left">Not known</p></td><td style="height:13.8pt; vertical-align:top; width:360.8pt"><p style="margin-left:5.4pt; text-align:left">Vasculitis</p></td></tr><tr><td style="height:13.6pt; vertical-align:top; width:437.6pt" colspan="2"><p style="text-align:left"><strong>Gastrointestinal disorders</strong></p></td></tr></tbody></table><p style="margin-left:0cm; margin-right:0cm; text-align:left">&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="height:13.6pt; vertical-align:top; width:76.8pt"><p style="text-align:left">Uncommon</p></td><td style="height:13.6pt; vertical-align:top; width:186.9pt"><p style="margin-left:5.4pt; text-align:left">Abdominal pain</p></td></tr><tr><td style="height:13.75pt; vertical-align:top; width:263.7pt" colspan="2"><p style="text-align:left"><strong>Hepatobiliary disorders</strong></p></td></tr><tr><td style="height:13.8pt; vertical-align:top; width:76.8pt"><p style="text-align:left">Not known</p></td><td style="height:13.8pt; vertical-align:top; width:186.9pt"><p style="margin-left:5.4pt; text-align:left">Elevation of liver function values</p></td></tr><tr><td style="height:13.75pt; vertical-align:top; width:263.7pt" colspan="2"><p style="text-align:left"><strong>Skin and subcutaneous tissue disorders</strong></p></td></tr><tr><td style="height:13.8pt; vertical-align:top; width:76.8pt"><p style="text-align:left">Not known</p></td><td style="height:13.8pt; vertical-align:top; width:186.9pt"><p style="margin-left:5.4pt; text-align:left">Angioedema, rash, pruritus</p></td></tr><tr><td style="height:13.8pt; vertical-align:top; width:263.7pt" colspan="2"><p style="text-align:left"><strong>Renal and urinary disorders</strong></p></td></tr><tr><td style="height:13.6pt; vertical-align:top; width:76.8pt"><p style="text-align:left">Not known</p></td><td style="height:13.6pt; vertical-align:top; width:186.9pt"><p style="margin-left:5.4pt; text-align:left">Renal failure</p></td></tr></tbody></table><p style="margin-left:0cm; margin-right:0cm; text-align:left">&nbsp;</p><p style="text-align:left">Table 3. Frequency of adverse reactions with hydrochlorothiazide</p><p style="text-align:left">&nbsp;</p><p style="margin-left:34pt; margin-right:20.1pt; text-align:left">Hydrochlorothiazide has been extensively prescribed for many years, frequently in higher doses than those administered with <strong>Diostar- plus</strong><strong>&reg;</strong>. The following adverse reactions have been reported in patients treated with monotherapy of thiazide diuretics, including hydrochlorothiazide:</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="height:13.6pt; vertical-align:top; width:442.3pt" colspan="2"><p style="text-align:left"><strong>Blood and lymphatic system disorders</strong></p></td></tr><tr><td style="height:13.8pt; vertical-align:top; width:79.6pt"><p style="text-align:left">Rare</p></td><td style="height:13.8pt; vertical-align:top; width:362.7pt"><p style="margin-left:12.95pt; text-align:left">Thrombocytopenia sometimes with purpura</p></td></tr><tr><td style="height:27.55pt; vertical-align:top; width:79.6pt"><p style="text-align:left">Very rare</p></td><td style="height:27.55pt; vertical-align:top; width:362.7pt"><p style="margin-left:12.95pt; margin-right:9.2pt; text-align:left">Agranulocytosis, leucopenia, haemolytic anaemia, bone marrow failure</p></td></tr><tr><td style="height:13.8pt; vertical-align:top; width:79.6pt"><p style="text-align:left">Not known</p></td><td style="height:13.8pt; vertical-align:top; width:362.7pt"><p style="margin-left:12.95pt; text-align:left">Aplastic anemia</p></td></tr><tr><td style="height:13.75pt; vertical-align:top; width:442.3pt" colspan="2"><p style="text-align:left"><strong>Immune system disorders</strong></p></td></tr><tr><td style="height:13.8pt; vertical-align:top; width:79.6pt"><p style="text-align:left">Very rare</p></td><td style="height:13.8pt; vertical-align:top; width:362.7pt"><p style="margin-left:12.95pt; text-align:left">Hypersensitivity reactions</p></td></tr><tr><td style="height:13.8pt; vertical-align:top; width:442.3pt" colspan="2"><p style="text-align:left"><strong>Metabolism and nutrition disorders</strong></p></td></tr><tr><td style="height:27.6pt; vertical-align:top; width:79.6pt"><p style="margin-right:22.55pt; text-align:left">Very common</p></td><td style="height:27.6pt; vertical-align:top; width:362.7pt"><p style="margin-left:12.95pt; text-align:left">Hypokalaemia, blood lipids increased (mainly at higher doses)</p></td></tr><tr><td style="height:13.75pt; vertical-align:top; width:79.6pt"><p style="text-align:left">Common</p></td><td style="height:13.75pt; vertical-align:top; width:362.7pt"><p style="margin-left:12.95pt; text-align:left">Hyponatraemia, hypomagnesaemia, hyperuricaemia</p></td></tr><tr><td style="height:27.6pt; vertical-align:top; width:79.6pt"><p style="text-align:left">Rare</p></td><td style="height:27.6pt; vertical-align:top; width:362.7pt"><p style="margin-left:12.95pt; text-align:left">Hypercalcaemia, hyperglycaemia, glycosuria and worsening of diabetic metabolic state</p></td></tr><tr><td style="height:13.8pt; vertical-align:top; width:79.6pt"><p style="text-align:left">Very rare</p></td><td style="height:13.8pt; vertical-align:top; width:362.7pt"><p style="margin-left:12.95pt; text-align:left">Hypochloraemic alkalosis</p></td></tr><tr><td style="height:13.75pt; vertical-align:top; width:442.3pt" colspan="2"><p style="text-align:left"><strong>Psychiatric disorders</strong></p></td></tr><tr><td style="height:13.8pt; vertical-align:top; width:79.6pt"><p style="text-align:left">Rare</p></td><td style="height:13.8pt; vertical-align:top; width:362.7pt"><p style="margin-left:12.95pt; text-align:left">Depression, sleep disturbances</p></td></tr><tr><td style="height:13.8pt; vertical-align:top; width:442.3pt" colspan="2"><p style="text-align:left"><strong>Nervous system disorders</strong></p></td></tr><tr><td style="height:13.75pt; vertical-align:top; width:79.6pt"><p style="text-align:left">Rare</p></td><td style="height:13.75pt; vertical-align:top; width:362.7pt"><p style="margin-left:12.95pt; text-align:left">Headache, dizziness, paraesthesia</p></td></tr><tr><td style="height:27.6pt; vertical-align:top; width:79.6pt"><p style="margin-right:13.9pt; text-align:left"><strong>Eye disorders</strong></p></td><td style="height:27.6pt; vertical-align:top; width:362.7pt"><p style="margin-left:0cm; text-align:left">&nbsp;</p></td></tr><tr><td style="height:13.8pt; vertical-align:top; width:79.6pt"><p style="text-align:left">Rare</p></td><td style="height:13.8pt; vertical-align:top; width:362.7pt"><p style="margin-left:12.95pt; text-align:left">Visual impairment</p></td></tr><tr><td style="height:13.75pt; vertical-align:top; width:79.6pt"><p style="text-align:left">Not known</p></td><td style="height:13.75pt; vertical-align:top; width:362.7pt"><p style="margin-left:12.95pt; text-align:left">Acute angle-closure glaucoma</p></td></tr><tr><td style="height:13.8pt; vertical-align:top; width:442.3pt" colspan="2"><p style="text-align:left"><strong>Cardiac disorders</strong></p></td></tr><tr><td style="height:13.8pt; vertical-align:top; width:79.6pt"><p style="text-align:left">Rare</p></td><td style="height:13.8pt; vertical-align:top; width:362.7pt"><p style="margin-left:12.95pt; text-align:left">Cardiac arrhythmias</p></td></tr><tr><td style="height:13.75pt; vertical-align:top; width:442.3pt" colspan="2"><p style="text-align:left"><strong>Vascular disorders</strong></p></td></tr><tr><td style="height:13.8pt; vertical-align:top; width:79.6pt"><p style="text-align:left">Common</p></td><td style="height:13.8pt; vertical-align:top; width:362.7pt"><p style="margin-left:12.95pt; text-align:left">Postural hypotension</p></td></tr><tr><td style="height:13.75pt; vertical-align:top; width:442.3pt" colspan="2"><p style="text-align:left"><strong>Respiratory, thoracic and mediastinal disorders</strong></p></td></tr><tr><td style="height:27.4pt; vertical-align:top; width:79.6pt"><p style="text-align:left">Very rare</p></td><td style="height:27.4pt; vertical-align:top; width:362.7pt"><p style="margin-left:12.95pt; margin-right:41.25pt; text-align:left">Respiratory distress including pneumonitis and pulmonary oedema</p></td></tr></tbody></table><p style="margin-left:0cm; margin-right:0cm; text-align:left">&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="height:13.6pt; vertical-align:top; width:390.95pt" colspan="2"><p style="text-align:left"><strong>Gastrointestinal disorders</strong></p></td></tr><tr><td style="height:13.8pt; vertical-align:top; width:88.8pt"><p style="text-align:left">Common</p></td><td style="height:13.8pt; vertical-align:top; width:302.15pt"><p style="margin-left:22.1pt; text-align:left">Loss of appetite, mild nausea and vomiting</p></td></tr><tr><td style="height:13.8pt; vertical-align:top; width:88.8pt"><p style="text-align:left">Rare</p></td><td style="height:13.8pt; vertical-align:top; width:302.15pt"><p style="margin-left:22.1pt; text-align:left">Constipation, gastrointestinal discomfort, diarrhoea</p></td></tr><tr><td style="height:13.75pt; vertical-align:top; width:88.8pt"><p style="text-align:left">Very rare</p></td><td style="height:13.75pt; vertical-align:top; width:302.15pt"><p style="margin-left:22.1pt; text-align:left">Pancreatitis</p></td></tr><tr><td style="height:13.8pt; vertical-align:top; width:390.95pt" colspan="2"><p style="text-align:left"><strong>Hepatobiliary disorders</strong></p></td></tr><tr><td style="height:13.8pt; vertical-align:top; width:88.8pt"><p style="text-align:left">Rare</p></td><td style="height:13.8pt; vertical-align:top; width:302.15pt"><p style="margin-left:22.1pt; text-align:left">Intrahepatic cholestasis or jaundice</p></td></tr><tr><td style="height:41.4pt; vertical-align:top; width:88.8pt"><p style="margin-right:20.45pt; text-align:left"><strong>Renal and urinary disorders</strong></p></td><td style="height:41.4pt; vertical-align:top; width:302.15pt"><p style="margin-left:0cm; text-align:left">&nbsp;</p></td></tr><tr><td style="height:13.75pt; vertical-align:top; width:88.8pt"><p style="text-align:left">Not known</p></td><td style="height:13.75pt; vertical-align:top; width:302.15pt"><p style="margin-left:22.1pt; text-align:left">Renal dysfunction, acute renal failure</p></td></tr><tr><td style="height:13.75pt; vertical-align:top; width:390.95pt" colspan="2"><p style="text-align:left"><strong>Skin and subcutaneous tissue disorders</strong></p></td></tr><tr><td style="height:13.6pt; vertical-align:top; width:88.8pt"><p style="text-align:left">Common</p></td><td style="height:13.6pt; vertical-align:top; width:302.15pt"><p style="margin-left:22.1pt; text-align:left">Urticaria and other forms of rash</p></td></tr></tbody></table><p style="text-align:left">&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="height:13.6pt; vertical-align:top; width:88.8pt"><p style="text-align:left">Rare</p></td><td style="height:13.6pt; vertical-align:top; width:357.0pt"><p style="margin-left:22.1pt; text-align:left">Photosensitisation</p></td></tr><tr><td style="height:41.35pt; vertical-align:top; width:88.8pt"><p style="text-align:left">Very rare</p></td><td style="height:41.35pt; vertical-align:top; width:357.0pt"><p style="margin-left:22.1pt; margin-right:9.05pt; text-align:left">Necrotising vasculitis and toxic epidermal necrolysis, cutaneous lupus erythematosus-like reactions, reactivation of cutaneous lupus erythematosus</p></td></tr><tr><td style="height:13.75pt; vertical-align:top; width:88.8pt"><p style="text-align:left">Not known</p></td><td style="height:13.75pt; vertical-align:top; width:357.0pt"><p style="margin-left:22.1pt; text-align:left">Erythema multiforme</p></td></tr><tr><td style="height:13.8pt; vertical-align:top; width:445.8pt" colspan="2"><p style="text-align:left"><strong>General disorders and administration site conditions</strong></p></td></tr><tr><td style="height:13.75pt; vertical-align:top; width:88.8pt"><p style="text-align:left">Not known</p></td><td style="height:13.75pt; vertical-align:top; width:357.0pt"><p style="margin-left:22.1pt; text-align:left">Pyrexia, asthenia</p></td></tr><tr><td style="height:13.75pt; vertical-align:top; width:445.8pt" colspan="2"><p style="text-align:left"><strong>Musculoskeletal and connective tissue disorders</strong></p></td></tr><tr><td style="height:13.8pt; vertical-align:top; width:88.8pt"><p style="text-align:left">Not known</p></td><td style="height:13.8pt; vertical-align:top; width:357.0pt"><p style="margin-left:22.1pt; text-align:left">Muscle spasm</p></td></tr><tr><td style="height:13.75pt; vertical-align:top; width:445.8pt" colspan="2"><p style="text-align:left"><strong>Reproductive system and breast disorders</strong></p></td></tr><tr><td style="height:13.6pt; vertical-align:top; width:88.8pt"><p style="text-align:left">Common</p></td><td style="height:13.6pt; vertical-align:top; width:357.0pt"><p style="margin-left:22.1pt; text-align:left">Impotence</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:left"><em>Symptoms</em></p><p style="margin-right:16.7pt; text-align:left">Overdose with valsartan may result in marked hypotension, which could lead to depressed level of consciousness, circulatory collapse and/or shock. In addition, the following signs and symptoms may occur due to an overdose of the hydrochlorothiazide component: nausea, somnolence, hypovolaemia, and electrolyte disturbances associated with cardiac arrhythmias and muscle spasms.</p><p style="text-align:left"><em>Treatment</em></p><p style="margin-right:18.8pt; text-align:left">The therapeutic measures depend on the time of ingestion and the type and severity of the symptoms, stabilisation of the circulatory condition being of prime importance.</p><p style="margin-right:11.35pt; text-align:left">If hypotension occurs, the patient should be placed in the supine position and salt and volume supplementation should be given rapidly.</p><p style="text-align:left">Valsartan cannot be eliminated by means of haemodialysis because of its strong plasma binding behaviour whereas clearance of hydrochlorothiazide will be achieved by &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp; dialysis.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-right:20.8pt; text-align:left">Pharmacotherapeutic group: Angiotensin II antagonists and diuretics, valsartan and diuretics; ATC Code: C09D A03</p><p style="margin-left:0cm; text-align:left">&nbsp;</p><p style="text-align:left">Valsartan/hydrochlorothiazide 80/12.5 mg Tablets only:</p><p style="margin-right:28.05pt; text-align:left">In a double-blind, randomised, active-controlled trial in patients not adequately controlled on hydrochlorothiazide 12.5 mg, significantly greater mean systolic/diastolic BP reductions were observed with the combination of valsartan/hydrochlorothiazide 80/12.5 mg (14.9/11.3 mmHg) compared to hydrochlorothiazide 12.5 mg (5.2/2.9 mmHg) and hydrochlorothiazide 25 mg (6.8/5.7 mmHg). In addition, a significantly greater percentage of patients</p><p style="text-align:left">&nbsp;</p><p style="margin-left:34pt; margin-right:20.8pt; text-align:left">responded (diastolic BP &lt;90 mmHg or reduction &ge;10 mmHg) with valsartan/hydrochlorothiazide 80/12.5 mg (60%) compared to hydrochlorothiazide 12.5 mg (25%) and hydrochlorothiazide 25 mg (27%).</p><p style="margin-right:18.75pt; text-align:left">In a double-blind, randomised, active-controlled trial in patients not adequately controlled on valsartan 80 mg, significantly greater mean systolic/diastolic BP reductions were observed with the combination of valsartan/hydrochlorothiazide 80/12.5 mg (9.8/8.2 mmHg) compared to valsartan 80 mg (3.9/5.1 mmHg) and valsartan 160 mg (6.5/6.2 mmHg). In addition, a significantly greater percentage of patients responded (diastolic BP &lt;90 mmHg or reduction &ge;10 mmHg) with valsartan/hydrochlorothiazide 80/12.5 mg (51%) compared to valsartan 80 mg (36%) and valsartan 160 mg (37%).</p><p style="margin-right:15.15pt; text-align:left">In a double-blind, randomised, placebo-controlled, factorial design trial comparing various dose combinations of valsartan/hydrochlorothiazide to their respective components, significantly greater mean systolic/diastolic BP reductions were observed with the combination of valsartan/hydrochlorothiazide 80/12.5 mg (16.5/11.8 mmHg) compared to placebo (1.9/4.1 mmHg) and both hydrochlorothiazide 12.5 mg (7.3/7.2 mmHg) and valsartan 80 mg (8.8/8.6 mmHg). In addition, a significantly greater percentage of patients responded (diastolic BP &lt;90 mmHg or reduction &ge;10 mmHg) with valsartan/hydrochlorothiazide 80/12.5 mg (64%) compared to placebo (29%) and hydrochlorothiazide (41%).</p><p style="margin-left:34pt; margin-right:29.5pt; text-align:left"><strong><em>Valsartan/hydrochlorothiazide 160/12.5 mg and 160/25mg Tablets only: </em></strong>In a double-blind, randomised, active-controlled trial in patients not adequately controlled on hydrochlorothiazide 12.5 mg, significantly greater mean</p><p style="margin-right:12.85pt; text-align:left">systolic/diastolic BP reductions were observed with the combination of valsartan/ hydrochlorothiazide 160/12.5 mg (12.4/7.5 mmHg) compared to hydrochlorothiazide 25 mg (5.6/2.1 mmHg). In addition, a significantly greater percentage of patients responded (BP &lt;140/90 mmHg or SBP reduction &ge;20 mmHg or DBP reduction &ge;10 mmHg) with valsartan/hydrochlorothiazide 160/12.5 mg (50%) compared to hydrochlorothiazide 25 mg (25%).</p><p style="margin-right:11.4pt; text-align:left">In a double-blind, randomised, active-controlled trial in patients not adequately controlled on valsartan 160 mg, significantly greater mean systolic/diastolic BP reductions were observed with both the combination of valsartan/hydrochlorothiazide 160/25 mg (14.6/11.9 mmHg) and valsartan/hydrochlorothiazide 160/12.5 mg (12.4/10.4 mmHg) compared to valsartan 160 mg (8.7/8.8 mmHg). The difference in BP reductions between the 160/25 mg and 160/12.5 mg doses also reached statistical</p><p style="margin-left:34pt; margin-right:16.05pt; text-align:left">significance. In addition, a significantly greater percentage of patients responded (diastolic BP &lt;90 mmHg or reduction &ge;10 mmHg) with valsartan/hydrochlorothiazide 160/25 mg (68%) and 160/12.5 mg (62%) compared to valsartan 160 mg (49%).</p><p style="margin-right:18.1pt; text-align:left">In a double-blind, randomised, placebo-controlled, factorial design trial comparing various dose combinations of valsartan/hydrochlorothiazide to their respective components, significantly greater mean systolic/diastolic BP reductions were observed with the combination of valsartan/hydrochlorothiazide 160/12.5 mg (17.8/13.5 mmHg) and 160/25 mg (22.5/15.3 mmHg) compared to</p><p style="text-align:left">&nbsp;</p><p style="margin-left:34pt; margin-right:20.8pt; text-align:left">placebo (1.9/4.1 mmHg) and the respective monotherapies, i.e., hydrochlorothiazide 12.5 mg (7.3/7.2 mmHg), hydrochlorothiazide 25 mg (12.7/9.3 mmHg) and valsartan 160 mg (12.1/9.4 mmHg). In addition, a significantly greater percentage of patients responded (diastolic BP &lt;90 mmHg or reduction &ge;10 mmHg) with valsartan/hydrochlorothiazide 160/25 mg (81%) and valsartan/hydrochlorothiazide 160/12.5 mg (76%) compared to placebo (29%) and the respective monotherapies, i.e., hydrochlorothiazide 12.5 mg (41%), hydrochlorothiazide 25 mg (54%), and valsartan 160 mg (59%).</p><p style="text-align:left">Valsartan/hydrochlorothiazide&nbsp;&nbsp; 80/12.5mg, 160/12.5 mg and 160/25mg Tablets:</p><p style="margin-right:15.4pt; text-align:left">Dose-dependent decreases in serum potassium occurred in controlled clinical studies with valsartan + hydrochlorothiazide. Reduction in serum potassium occurred more frequently in patients given 25 mg hydrochlorothiazide than in those given 12.5 mg hydrochlorothiazide. In controlled clinical trials with valsartan/hydrochlorothiazide the potassium lowering effect of hydrochlorothiazide was attenuated by the potassium-sparing effect of valsartan. Beneficial effects of valsartan in combination with hydrochlorothiazide on cardiovascular mortality and morbidity are currently unknown.</p><p style="text-align:left">Epidemiological studies have shown that long-term treatment with hydrochlorothiazide reduces the risk of cardiovascular mortality and morbidity.</p><p style="margin-left:0cm; text-align:left">&nbsp;</p><p style="text-align:left">Valsartan</p><p style="margin-right:22.55pt; text-align:left">Valsartan is an orally active and specific angiotensin II (Ang II) receptor antagonist. It acts selectively on the AT1 receptor subtype, which is responsible for the known actions of angiotensin II. The increased plasma levels of Ang II following AT1receptor blockade with valsartan may stimulate the unblocked AT2 receptor, which appears to counterbalance the effect of the AT1 receptor.</p><p style="margin-right:11.4pt; text-align:left">Valsartan does not exhibit any partial agonist activity at the AT1 receptor and has much (about 20,000 fold) greater affinity for the AT1 receptor than for the AT2 receptor. Valsartan is not known to bind to or block other hormone receptors or ion channels known to be important in cardiovascular regulation.</p><p style="margin-left:34pt; margin-right:12.45pt; text-align:left">Valsartan does not inhibit ACE, also known as kininase II, which converts Ang I to Ang II and degrades bradykinin. Since there is no effect on ACE and no potentiation of bradykinin or substance P, angiotensin II antagonists are unlikely to be associated with coughing. In clinical trials where valsartan was compared with an ACE inhibitor, the incidence of dry cough was significantly (P &lt;0.05) lower in patients treated with valsartan than in those treated with an ACE inhibitor (2.6% versus 7.9% respectively). In a clinical trial of patients with a history of dry cough during ACE inhibitor therapy, 19.5% of trial subjects receiving valsartan and 19.0% of those receiving a thiazide</p><p style="text-align:left">diuretic experienced cough compared to 68.5% of those treated with an ACE inhibitor (P &lt;0.05).</p><p style="margin-right:12.75pt; text-align:left">Administration of valsartan to patients with hypertension results in reduction of blood pressure without affecting pulse rate. In most patients, after administration of a single oral dose, onset of antihypertensive activity occurs within 2 hours, and the peak reduction of blood pressure is achieved within 4-6 hours. The</p><p style="text-align:left">&nbsp;</p><p style="margin-left:34pt; margin-right:22.75pt; text-align:left">antihypertensive effect persists over 24 hours after dosing. During repeated dosing, the maximum reduction in blood pressure with any dose is generally attained within 2-4 weeks and is sustained during long-term therapy. Combined with hydrochlorothiazide, a significant additional reduction in blood pressure is achieved.</p><p style="margin-right:20.8pt; text-align:left">Abrupt withdrawal of valsartan has not been associated with rebound hypertension or other adverse clinical events.</p><p style="margin-right:14.25pt; text-align:left">In hypertensive patients with type 2 diabetes and microalbuminuria, valsartan has been shown to reduce the urinary excretion of albumin. The MARVAL (Micro Albuminuria Reduction with Valsartan) study assessed the reduction in urinary albumin excretion (UAE) with valsartan (80-160 mg/od) versus amlodipine (5-10 mg/od), in 332 type 2 diabetic patients (mean age: 58 years; 265 men) with microalbuminuria (valsartan: 58 &micro;g/min; amlodipine: 55.4 &micro;g/min), normal or high blood pressure and with preserved renal function (blood creatinine &lt;120 &micro;mol/l). At 24 weeks, UAE was reduced (p &lt;0.001) by 42% (&ndash;24.2 &micro;g/min; 95% CI: &ndash;40.4</p><p style="margin-left:34pt; margin-right:18.1pt; text-align:left">to &ndash;19.1) with valsartan and approximately 3% (&ndash;1.7 &micro;g/min; 95% CI: &ndash;5.6 to 14.9) with amlodipine despite similar rates of blood pressure reduction in both groups. The Valsartan Reduction of Proteinuria (DROP) study further examined the efficacy of valsartan in reducing UAE in 391 hypertensive patients (BP=150/88 mmHg) with type 2 diabetes, albuminuria (mean=102 &micro;g/min; 20&ndash;700 &micro;g/min) and preserved renal function (mean serum creatinine = 80</p><p style="margin-right:13.65pt; text-align:left">&micro;mol/l). Patients were randomised to one of 3 doses of valsartan (160, 320 and 640 mg/od) and treated for 30 weeks. The purpose of the study was to determine the optimal dose of valsartan for reducing UAE in hypertensive patients with type 2 diabetes. At 30 weeks, the percentage change in UAE was significantly reduced by 36% from baseline with valsartan 160 mg (95%CI: 22 to 47%), and by 44% with valsartan 320 mg (95%CI: 31 to 54%). It was concluded that</p><p style="margin-right:54.1pt; text-align:left">160-320 mg of valsartan produced clinically relevant reductions in UAE in hypertensive patients with type 2 diabetes.</p><p style="margin-left:0cm; text-align:left">&nbsp;</p><p style="text-align:left">Hydrochlorothiazide</p><p style="margin-left:34pt; margin-right:12.7pt; text-align:left">The site of action of thiazide diuretics is primarily in the renal distal convoluted tubule. It has been shown that there is a high-affinity receptor in the renal cortex as the primary binding site for the thiazide diuretic action and inhibition of NaCl transport in the distal convoluted tubule. The mode of action of thiazides is through inhibition of the Na+Cl- symporter perhaps by competing for the Cl- site, thereby affecting electrolyte reabsorption mechanisms:directly increasing sodium and chloride excretion to an approximately equal extent, and indirectly by this diuretic action reducing plasma volume, with consequent increases in plasma renin activity, aldosterone secretion and urinary potassium loss, and a decrease in serum potassium. The renin-aldosterone link is mediated by angiotensin II, so with co-administration of valsartan the reduction</p><p style="text-align:left">in serum potassium is less pronounced as observed under monotherapy with hydrochlorothiazide.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:34pt; margin-right:0cm; text-align:left"><em>Valsartan/hydrochlorothiazide</em></p><p style="margin-left:34pt; margin-right:24.4pt; text-align:left">The systemic availability of hydrochlorothiazide is reduced by about 30% when co-administered with valsartan. The kinetics of valsartan are not markedly affected by the co-administration of hydrochlorothiazide. This observed interaction has no impact on the combined use of valsartan and hydrochlorothiazide, since controlled clinical trials have shown a clear</p><p style="text-align:left">anti-hypertensive effect, greater than that obtained with either active substance given alone, or placebo.</p><p style="margin-left:0cm; margin-right:0cm; text-align:left">&nbsp;</p><p style="margin-left:34pt; margin-right:385.6pt; text-align:left"><em>Valsartan Absorption</em></p><p style="margin-left:34pt; margin-right:13.4pt; text-align:left">Following oral administration of valsartan alone, peak plasma concentrations of valsartan are reached in 2&ndash;4 hours. Mean absolute bioavailability is 23%. Food decreases exposure (as measured by AUC) to valsartan by about 40% and peak plasma concentration (Cmax) by about 50%, although from about 8 h post dosing plasma valsartan concentrations are similar for the fed and fasted groups. This reduction in AUC is not, however, accompanied by a clinically significant reduction in the therapeutic effect, and valsartan can therefore be given either with or without food.</p><p style="margin-left:34pt; text-align:left"><em>Distribution</em></p><p style="margin-left:34pt; margin-right:11.4pt; text-align:left">The steady-state volume of distribution of valsartan after intravenous administration is about 17 litres, indicating that valsartan does not distribute into tissues extensively. Valsartan is highly bound to serum proteins (94 &ndash; 97%), mainly serum albumin.</p><p style="margin-left:34pt; text-align:left"><em>Biotransformation</em></p><p style="margin-left:34pt; margin-right:11.4pt; text-align:left">Valsartan is not biotransformed to a high extent as only about 20% of dose is recovered as metabolites. A hydroxy metabolite has been identified in plasma at low concentrations (less than 10% of the valsartan AUC). This metabolite is pharmacologically inactive.</p><p style="margin-left:34pt; text-align:left"><em>Elimination</em></p><p style="margin-left:34pt; margin-right:20.1pt; text-align:left">Valsartan shows multiexponential decay kinetics (t&frac12;&alpha; &lt;1 h and t&frac12;&szlig; about 9 h). Valsartan is primarily eliminated in faeces (about 83% of dose) and urine (about 13% of dose), mainly as unchanged drug. Following intravenous administration, plasma clearance of valsartan is about 2 l/h and its renal clearance is 0.62 l/h (about 30% of total clearance). The half-life of valsartan is 6 hours.</p><p style="margin-left:0cm; margin-right:0cm; text-align:left">&nbsp;</p><p style="margin-left:34pt; margin-right:336.9pt; text-align:left"><em>Hydrochlorothiazide Absorption</em></p><p style="margin-left:34pt; margin-right:22.05pt; text-align:left">The absorption of hydrochlorothiazide, after an oral dose, is rapid (tmax about 2 h). The increase in mean AUC is linear and dose proportional in the therapeutic range.</p><p style="margin-right:41.45pt; text-align:left">The effect of food on hydrochlorothiazide absorption, if any, has little clinical significance. Absolute bioavailability of hydrochlorothiazide is 70% after oral administration.</p><p style="margin-left:34pt; text-align:left"><em>Distribution</em></p><p style="text-align:left">&nbsp;</p><p style="text-align:left">The apparent volume of distribution is 4&ndash;8 l/kg.</p><p style="margin-right:37.45pt; text-align:left">Circulating hydrochlorothiazide is bound to serum proteins (40&ndash;70%), mainly serum albumin. Hydrochlorothiazide also accumulates in erythrocytes at approximately 3 times the level in plasma.</p><p style="margin-left:34pt; text-align:left"><em>Elimination</em></p><p style="margin-left:34pt; margin-right:18.1pt; text-align:left">Hydrochlorothiazide is eliminated predominantly as unchanged drug. Hydrochlorothiazide is eliminated from plasma with a half-life averaging 6 to 15 hours in the terminal elimination phase. There is no change in the kinetics of hydrochlorothiazide on repeated dosing, and accumulation is minimal when dosed once daily. There is more than 95% of the absorbed dose being excreted as unchanged compound in the urine. The renal clearance is composed of passive filtration and active secretion into the renal tubule.</p><p style="margin-left:0cm; margin-right:0cm; text-align:left">&nbsp;</p><p style="margin-left:34pt; margin-right:338.9pt; text-align:left"><em>Special populations Elderly</em></p><p style="margin-left:34pt; margin-right:20.8pt; text-align:left">A somewhat higher systemic exposure to valsartan was observed in some elderly subjects than in young subjects; however, this has not been shown to have any clinical significance.</p><p style="margin-right:31.4pt; text-align:left">Limited data suggest that the systemic clearance of hydrochlorothiazide is reduced in both healthy and hypertensive elderly subjects compared to young healthy volunteers.</p><p style="margin-left:34pt; text-align:left"><em>Renal impairment</em></p><p style="text-align:left">At the recommended dose of <strong>Diostar- plus</strong><strong>&reg; </strong>no dose adjustment is required for patients with a Glomerular Filtration Rate (GFR) of 30&ndash;70 ml/min.</p><p style="margin-left:34pt; margin-right:11.4pt; text-align:left">In patients with severe renal impairment (GFR &lt;30 ml/min) and patients undergoing dialysis no data are available for <strong>Diostar- plus</strong><strong>&reg;</strong>. Valsartan is highly bound to plasma protein and is not to be removed by dialysis, whereas clearance of hydrochlorothiazide will be achieved by dialysis.</p><p style="margin-right:13.4pt; text-align:left">In the presence of renal impairment, mean peak plasma levels and AUC values of hydrochlorothiazide are increased and the urinary excretion rate is reduced. In patients with mild to moderate renal impairment, a 3-fold increase in hydrochlorothiazide AUC has been observed. In patients with severe renal impairment an 8-fold increase in AUC has been observed. Hydrochlorothiazide is contraindicated in patients with severe renal impairment (see section 4.3).</p><p style="margin-left:34pt; text-align:left"><em>Hepatic impairment</em></p><p style="margin-left:34pt; margin-right:12.75pt; text-align:left">In a pharmacokinetics trial in patients with mild (n=6) to moderate (n=5) hepatic dysfunction, exposure to valsartan was increased approximately 2-fold compared with healthy volunteers (see sections 4.2 and 4.4).</p><p style="margin-right:16.7pt; text-align:left">There is no data available on the use of valsartan in patients with severe hepatic dysfunction (see section 4.3). Hepatic disease does not significantly affect the pharmacokinetics of hydrochlorothiazide.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-right:15.15pt; text-align:left">The potential toxicity of the valsartan - hydrochlorothiazide combination after oral administration was investigated in rats and marmosets in studies lasting up to six months. No findings emerged that would exclude the use of therapeutic doses in man.</p><p style="margin-right:15.4pt; text-align:left">The changes produced by the combination in the chronic toxicity studies are most likely to have been caused by the valsartan component. The toxicological target organ was the kidney, the reaction being more marked in the marmoset than the rat. The combination led to kidney damage (nephropathy with tubular basophilia, rises in plasma urea, plasma creatinine and serum potassium, increases in urine volume and urinary electrolytes from 30 mg/kg/day valsartan + 9 mg/kg/day hydrochlorothiazide in rats and 10 + 3 mg/kg/d in marmosets), probably by way of altered renal haemodynamics. These doses in rat, respectively, represent 0.9 and 3.5&ndash;times the maximum recommended human dose (MRHD) of valsartan and hydrochlorothiazide on a mg/m2 basis. These doses in marmoset, respectively, represent 0.3 and 1.2&ndash;times the maximum recommended human dose (MRHD) of valsartan and hydrochlorothiazide on a mg/m2 basis. (Calculations assume an oral dose of 320 mg/day valsartan in combination with 25 mg/day hydrochlorothiazide and a 60-kg patient.)</p><p style="margin-right:15.4pt; text-align:left">High doses of the valsartan - hydrochlorothiazide combination caused falls in red blood cell indices (red cell count, haemoglobin, haematocrit, from 100 + 31 mg/kg/d in rats and 30 + 9 mg/kg/d in marmosets). These doses in rat, respectively, represent 3.0 and 12 times the maximum recommended human dose (MRHD) of valsartan and hydrochlorothiazide on a mg/m2 basis. These doses in marmoset, respectively, represent 0.9 and 3.5 times the maximum recommended human dose (MRHD) of valsartan and hydrochlorothiazide on a mg/m2 basis. (Calculations assume an oral dose of 320 mg/day valsartan in combination with 25 mg/day hydrochlorothiazide and a 60-kg patient).</p><p style="margin-right:16.75pt; text-align:left">In marmosets, damage was observed in the gastric mucosa (from 30 + 9 mg/kg/d). The combination also led in the kidney to hyperplasia of the afferent aterioles (at 600 + 188 mg/kg/d in rats and from 30 + 9 mg/kg/d in marmosets). These doses in marmoset, respectively, represent 0.9 and 3.5 times the maximum recommended human dose (MRHD) of valsartan and hydrochlorothiazide on a mg/m2 basis. These doses in rat, respectively, represent 18 and 73 times the maximum recommended human dose (MRHD) of valsartan and hydrochlorothiazide on a mg/m2 basis. (Calculations assume an oral dose of 320 mg/day valsartan in combination with 25 mg/day hydrochlorothiazide and a 60-kg patient).</p><p style="margin-right:16.75pt; text-align:left">The above mentioned effects appear to be due to the pharmacological effects of high valsartan doses (blockade of angiotensin II-induced inhibition of renin release, with stimulation of the renin-producing cells) and also occur with ACE inhibitors. These findings appear to have no relevance to the use of therapeutic doses of valsartan in humans.</p><p style="margin-right:11.4pt; text-align:left">The valsartan - hydrochlorothiazide combination was not tested for mutagenicity, chromosomal breakage or carcinogenicity, since there is no evidence of interaction between the two substances. However, these tests were performed separately with valsartan and hydrochlorothiazide, and produced no evidence of mutagenicity, chromosomal breakage or carcinogenicity.</p><p style="margin-right:21.45pt; text-align:left">In rats, maternally toxic doses of valsartan (600 mg/kg/day) during the last days of gestation and lactation led to lower survival, lower weight gain and delayed development (pinna detachment and ear-canal opening) in the offspring (see section 4.6). These doses in rats (600 mg/kg/day) are approximately 18 times the maximum</p><p style="text-align:left">recommended human dose on a mg/m2 basis (calculations assume an oral dose of 320 mg/day and a 60-kg patient). Similar findings were seen with valsartan/hydrochlorothiazide in rats and rabbits. In embryo-fetal development (Segment II) studies with valsartan/hydrochlorothiazide in rat and rabbit, there was no evidence of teratogenicity; however, fetotoxicity associated with maternal toxicity was observed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:left">Microcrystalline cellulose, Croscarmellose sodium, Povidone K30, Colloidal silicon dioxide, Magnesium stearate, Opadry OY-L, FD&amp;C red # 40, FD&amp;C blue # 1.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:left">Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:left">Store below 30&deg;C.</p><p style="text-align:left">Store in the original package in order to protect from moisture</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:0cm; text-align:left">&nbsp;</p><p style="margin-right:30pt; text-align:left"><strong>Diostar-plus</strong><strong>&reg; </strong><strong>160 mg/12.5 mg </strong>are packed in Alu/Alu blister, intended for oral use.</p><p style="text-align:left">Pack size: 30 tablets (10 tablets / blister, 3 blister / pack)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:left">No special requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Pharma International Company Amman - Jordan
Tel: 00962-6-5158890 / 5157893
Fax: 00962-6-5154753
email: marketing@pic-jo.com
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                06/2014
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>